


 Cite this: *RSC Adv.*, 2026, 16, 617

Development of substituted 2-(4-(sulfonyl)piperazin-1-yl)quinazoline molecular hybrids as a new class of antimalarials

 Hari Madhav,^{†ab} Ashutosh Panda,^{†b} Dipanwita Datta,^b Kashfa Shaheen,^a Abdur Rahman,^c Azhar Tariq Khan,^a Souvik Bhattacharjee,^c Dhiraj Kumar,^b Pawan Malhotra^{*b} and Nasimul Hoda^{†*a}

The rapid emergence of drug resistance makes malaria elimination a global challenge despite the prevalence of artemisinin-based combination therapies (ACTs), thus highlighting the urgent need for the development of new antimalarials with novel modes of action. The present study aimed to develop new quinazoline hybrid antimalarials using bioactive small building blocks. The antimalarial activity results revealed that most molecular hybrids have IC₅₀ values below 10 μM for the drug-sensitive *Pf3D7* strain. The study identified molecular hybrids **19**, *N*-(2-chloro-4-((4-(4-((tetrahydrofuran-2-yl)methyl)amino)quinazolin-2-yl)piperazin-1-yl)sulfonyl)phenyl)acetamide and **27**, 2-(4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline as potent antimalarials with an IC₅₀ value of 3.4 μM and 2.9 μM against *Pf3D7*, respectively. The cytotoxicity investigation against mammalian A549 cells and activated macrophages derived from THP1 monocytes revealed that the compounds were relatively non-cytotoxic, and their antimalarial activity was not associated with cytotoxicity. *In silico* studies were conducted to predict plausible drug targets of the compounds, and the results suggested that the antimalarial activity of the compounds may be due to the inhibition of zinc metalloprotease *PfFLN*, with concurrent inhibition of cysteine proteases *PfFP2* and *PfFP3*. The MM-GBSA analysis revealed that the binding free energies of **19** and **27** with *PfFLN* were −50.3223 and −51.5066 kcal mol^{−1}, respectively. The predicted ADME properties of the compounds fall within the Schrödinger range, which encompasses 95% of all known medications. The study thus emphasised the significance of the molecular hybridisation approach and highlighted compounds **19** and **27** as potent hit molecules that could be further optimised for the development of new antimalarials.

 Received 5th November 2025
 Accepted 10th December 2025

DOI: 10.1039/d5ra08515b

rsc.li/rsc-advances

1. Introduction

Malaria is a life-threatening illness that contributed to 597 000 fatalities worldwide in 2023, with an increase of 10% over the previous three years.¹ Despite the artemisinin-based combination therapy's (ACTs) effectiveness, the rapid emergence of drug resistance to its constituent parts poses a serious challenge to the management and eradication of malaria.² Although there are new antimalarial medications in the clinical pipeline, it won't be long before they're widely accessible.³ A clinical trial (NCT 04546633) disclosed that one of the candidate drugs, KAF-156, was markedly potent against artemisinin-resistant

parasites in adults and is currently being investigated in Phase 2 studies in children when combined with the partner medication lumefantrine.⁴ Likewise, to challenge artemisinin resistance, the use of three ACTs was also investigated and found effective in clinical trials.^{5,6} Consequently, there is an urgent need for the development of new antimalarials with a novel mode of action to address the drug resistance towards mainline therapy ACTs.

A number of versatile scaffolds have been identified in medicinal chemistry that exhibit varied pharmacological activities against multiple pathogens. Quinazoline is one such scaffold that has been shown to be active against malaria,⁷ bacterial infections,^{8,9} cancer,¹⁰ hypertension and viral infections,¹¹ and tuberculosis.¹² For antimalarial development, Gilson, *et al.*¹³ disclosed 2-anilino 4-amino substituted quinazolines in nanomolar activity against *Pf3D7*, *PfAW2*, and potent oral *in vivo* activity. A study by Bouchut, *et al.*¹⁴ highlighted *in vitro* and *in vivo* antimalarial potential of quinazolines as DNA methyltransferase (DNMT3a) inhibitors. Similarly, Mizukawa, *et al.*¹¹ disclosed the nanomolar antimalarial 6,7-dimethoxyquinazoline-2,4-diamines up to 6 nM against *P.*

^aDrug Design and Synthesis Laboratory, Department of Chemistry, Jamia Millia Islamia, New Delhi-110025, India. E-mail: nhoda@jmi.ac.in

^bInternational Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi-110067, India. E-mail: pawanmal@gmail.com; pawanm@icgeb.res.in

^cSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi-110067, India

[†] These authors contributed equally to the article (Joint First Authors).


falciparum malaria. Artemisinin-quinazoline derivatives were also shown to be effective antimalarials by the study of Fröhlich, *et al.*¹⁵

Likewise, the sulphonamide functional group is frequently explored in medicinal chemistry, which has led to the development of efficient antibacterial, antiviral, and antifungal agents.¹⁶ The anticancer,¹⁷ antidepressant,¹⁸ antimalarials,¹⁹ antiproliferative,²⁰ and antitubercular²¹ potential of sulphonamides was also accounted for. Recently, Pingaew, *et al.*²² explored indole-sulphonamide hybrids as dual-acting agents for treating cancer and malaria. Similarly, Karpina, *et al.*²³ reported a series of ^{1,2,4} triazolo[4,3-*a*]pyridine sulfonamides as effective antimalarials and proposed them as inhibitors of PfFP2. Furthermore, the moiety 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine is highlighted as an important pharmacophore of Sitagliptin 24, a marketed drug for the treatment of type-II diabetes. The 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine was used in developing inhibitors of bromodomain-containing protein 4 (BRD-4),^{25,26} poly (ADP-ribose) polymerase-1 (PARP1), and anaplastic lymphoma kinase (ALK)²⁷ inhibitors for anti-cancer and cellular antiproliferative activity. Similarly, this group has also been reported as an important building block for developing antimicrobial²⁸ and potential anticonvulsant agents.²⁹ Tetrahydrofurfurylamine has proven to be a versatile and valuable building block in the design of new therapeutic agents. Shan, *et al.*³⁰ developed tetrahydrofurfurylamino derivatives of geldanamycin that were able to block hepatitis C virus (HCV) replication. Lawrence, *et al.*³¹ used the same building block to develop new anticancer molecules that inhibit the ACK1 enzyme. Elbadawi, *et al.*³² designed tetrahydrofurfurylamine-hybridised 2-arylquinolines that target both EGFR and FAK, offering another promising approach to cancer treatment. Similarly, Balam *et al.*³³ developed compounds combining tetrahydrofurfurylamine with *N*-(3-picolyl) benzoxazaphosphinamides, showing potential for treating metabolic disorders such as heart disease, obesity, and diabetes by inhibiting the 11 β -HSD1 enzyme. Collectively, these studies highlight the significant role of the tetrahydrofurfurylamine motif in tuning biological activity and enabling the development of therapeutically relevant compounds.

The polypharmacological properties of quinazolines, sulphonamides, tetrahydrofurfurylamine, and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine thus strongly highlight the biological importance of these small building blocks. Here, we designed a series of hybrid molecules using the above-mentioned biologically active building blocks and studied their antimalarial potential. The study thus advocates designing unique trifunctional hybrids through integration for the treatment of malaria and investigating their potential for the development of distinct antimalarials.

1.1. Design strategy and hypothesis

The molecular hybridisation approach was employed to design proposed quinazoline-sulphonamide hybrids by combining three biologically important small building blocks: quinazoline

as a core scaffold, substituted triazolo[4,3-*a*]pyrazine or tetrahydrofurfurylamine at the 4th position of quinazoline, and substituted sulphonamides at the 2nd position of the quinazoline. The significance of quinazolines for the development of new antimalarials could be underlined by the study of Gilson, *et al.*¹³ which disclosed that substitution at the 2nd and 4th positions of quinazolines plays a substantial role in tuning the antimalarial efficacy of the compounds. The compound **A**, 4-(((tetrahydrofuran-2-yl)methyl)amino)quinazolin-2-yl)amino benzamide of the study highlighted that the tetrahydrofurfurylamine at the 4th position of the quinazoline ring was fruitful to afford potent antimalarials with an EC₅₀ value of 0.691 μ M against the Pf3D7 strain, Fig. 1.

Similarly, Bouchut, *et al.*¹⁴ reported molecule **B**, *N*-(1-benzylpiperidin-4-yl)-2-(4-phenylpiperazin-1-yl)quinazolin-4-amine and underlined the significance of the quinazoline core for the development of new antimalarials. Moreover, our recent study revealed compound **C**, ethyl 7-methoxy-4-(((tetrahydrofuran-2-yl)methyl)amino)quinoline-3-carboxylate, which utilised tetrahydrofurfurylamine, displayed significant efficacy against the Pf3D7 strain with an IC₅₀ value of 3.96 μ M.³⁴ Furthermore, the substituted triazolo[4,3-*a*]pyrazine was also explored for the development of disease-modifying small molecules, such as Hu, *et al.*³⁵ reported compound **D**, (*S*)-*N*-(3-(1*H*-indol-3-yl)-1-oxo-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)propan-2-yl)benzenesulfonamide with an MIC of 32 and 16 μ g ml⁻¹ against *S. aureus* and *E. coli*, which highlighted the antibacterial potential of triazolo[4,3-*a*]pyrazine and aryl sulphonamide hybrids. Similarly, Raveesha, *et al.*³⁶ developed triazolo[4,3-*a*]pyrazine analogues and highlighted compound **F**, *N*-(2-fluoro-4-(trifluoromethyl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazine-7(8*H*)-carboxamide as promising anticancer agents with an IC₅₀ of 8.18 and 15.23 μ M against human colon cancer cell lines HT-29, and HCT-116, respectively. Hence, this building block was also utilised at the 4th position of the quinazoline core to explore its potential application in the identification of new antimalarials. Like compound **D**, the significance of sulphonamides was accounted for in several studies for the development of new antimalarial agents. Ezugwu, *et al.*¹⁹ reported compound **E**, (2*S*)-4-methyl-*N*-(3-methyl-1-oxo-1-(phenylamino)butan-2-yl)-2-((4-nitrophenyl) sulfonamido)pentanamide as a sulphonamide-based dipeptide antimalarial with 64.7% inhibition of parasitaemia in *P. berghet*-infected mice.¹⁹ As a result, sulphonamides' variable structure makes them great candidates for the development of new multi-target therapeutic molecules in the developing discipline of polypharmacology.

The emerging resistance to current mainline antimalarial drugs underscores the need for the development of new antimalarials with a novel mechanism of action. To combat multidrug-resistant parasite strains, the concept of hybridisation of two or more active pharmacophores into a single chemical entity displayed potential advantages over artemisinin-based combination therapy (ACT).³⁷ Therefore, keeping in mind the antimalarial potential of quinazoline,^{13,14} tetrahydrofurfurylamine,^{13,34} triazolo[4,3-*a*]pyrazine,³⁸ and sulphonamides^{19,23} through different drug targets, the current idea






Fig. 1 Design of new tetrahydrofurfurylamine/triazolo[4,3-*a*]pyrazine-quinazoline-sulphonamide hybrids.

was conceived to design a new hybrid antimalarial for the treatment of malaria. Combining them *via* a molecular hybridisation strategy at the quinazoline's C2 and C4 positions was expected to afford enhanced antimalarial activity through synergistic polypharmacology with a probable novel mechanism of action. This scaffold fills gaps in the antimalarial chemical space by introducing a trifunctional hybrid that has not been observed in literature.

Efforts were made to establish the structure–activity relationship (SAR) for antimalarial efficacy. The hybrids were screened against drug-sensitive and artemisinin-resistant strains of *P. falciparum*. The cytotoxicity of the hybrids was assessed


against lung cancer A549 cells and activated macrophages from THP1 monocytes. Additionally, the physicochemical characteristics and drug-likeness of the synthesised hybrids were also predicted.

2. Results and discussion

2.1. Chemistry


The multi-step synthetic protocol was followed to achieve target molecular hybrids as displayed in Schemes 1–6.

Substituted 4-acetamidobenzene-1-sulfonyl chlorides **5** (a–b), Scheme 1, were afforded by the acylation of different anilines



Scheme 1 Synthesis of substituted 4-acetamidobenzene-1-sulfonyl chlorides **5** (a–b). Reagents and conditions: (i) Et₃N, DCM, 0 °C – RT, 1.5 h; (ii) 0–60 °C, 3 h.







Scheme 2 Synthesis of 3-acetylbenzenesulfonyl chloride 7. Reagents and conditions: (i) 0–90 °C, 12 h.

in DCM in the presence of Et₃N, followed by reaction with chlorosulphonic acid at different temperatures. Likewise, 3-acetylbenzenesulfonyl chloride 7 was afforded by treating


chlorosulphonic acid with acetophenone, as shown in Scheme 2. On the other hand, as displayed in Scheme 3, 2,4-dichloroquinazoline 11 was synthesised by reacting urea with methyl anthranilate at high temperature, followed by chlorination with phosphorus oxychloride. Synthesised 2,4-dichloroquinazoline 11 was further reacted with tetrahydrofurfurylamine and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine, HCl to achieve respective intermediates 13 and 16. The intermediates 13 and 16 were further reacted with piperazine and morpholine to afford intermediates 14 (a–b) and 17 (a–b), as shown in Schemes 4 and 5. Finally, target quinazoline-sulphonamides 19–36 were obtained by reacting intermediates 14a and 17a with respective sulphonyl chlorides as shown in Scheme 6. The final structures



Scheme 3 Synthesis of 2,4-dichloroquinazoline 11. Reagents and conditions: (i) 180–210 °C, 3 h; (ii) POCl₃, DIPEA, RT – 90 °C, 6 h.




Scheme 4 Synthesis of substituted *N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine 14 (a–b). Reagents and conditions: (i) Et₃N, THF, 60 °C, 1 h; (ii) K₂CO₃, DMF, morpholine/piperazine, 95 °C, 12 h.



Scheme 5 Synthesis of substituted 4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline 17 (a–b). Reagents and conditions: (i) KOH, THF, 50 °C, 3 h; (ii) EtOH, Et₃N, morpholine/piperazine, 80 °C, 14 h.





Scheme 6 Synthesis of substituted quinazoline-sulphonamides 19–36. Reagents and conditions: (i) DMF, K₂CO₃, 70 °C, 3.5 h.

and antimalarial properties of compounds 19–36 are shown in Table 1.

The synthesised intermediates and target compounds were purified by column chromatography using silica gel (200–400) as the stationary phase. The chemical structures and molecular weight of the compounds were confirmed by NMR spectroscopy (Fig. S1–S48) and high-resolution mass spectrometry (HRMS) (Fig. S49–S72). The purified compounds were stored in a cool, dark place and used for biological studies.

2.2. Antimalarial study of the compounds

The antimalarial efficacy of the compounds was investigated against the drug-sensitive 3D7 strain of the *P. falciparum* (Pf3D7) parasite. The study used DMSO and chloroquine (CQ) as a control. The half-maximal inhibitory concentration (IC₅₀) of the compounds is shown in Table 1 and Fig. S73 and S74.

Results indicate that most of the compounds were able to inhibit the growth of drug-sensitive parasites with an IC₅₀ below 25 μM. A total of four compounds, 19, 21, 25, and 27, displayed an IC₅₀ value below 5 μM, while ten compounds, 14a, 14b, 17a, 20, 24, 28, 30, 31, 33, and 34, displayed an IC₅₀ value below 25 μM. The structure–activity relationship (SAR) study disclosed a compelling correlation between the structure of the compounds and their antimalarial activity. Substitution at 4th position of 2,4-dichloroquinazoline with tetrahydrofurfurylamine and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine resulted as compounds 13 and 16, respectively. Both compounds remained inactive against drug-sensitive *P. falciparum*, but further substitution with piperazine at the 2nd position of both compounds resulted in 14a and 17a, making both compounds active against Pf3D7 with an IC₅₀ value of 8.26 μM and 13.53 μM, respectively. The results of a subsequent SAR study showed that the bioactivity of 14b did not change significantly when the piperazine ring of 14a was replaced with morpholine, but it was lost in the case of 17b, indicating that the NH group of piperazine with triazolo[4,3-*a*]pyrazine at the 4th position of quinazoline was helpful in identifying the antimalarial potency of the compounds. In order to study the antimalarial potential of quinazoline-sulphonamide hybrids, intermediates 14a and 17a were hybridised with the substituted aromatic sulphonamides. The multiple substitutions were performed at the aromatic ring of sulphonamides to fine-tune the antimalarial efficacy of the compounds. In this order, compound 14a was hybridised with 4-acetamido-3-chlorobenzenesulfonyl chloride, and the low

micromolar antimalarial potency against Pf3D7 strain was obtained and identified as compound 19, with an IC₅₀ value of 3.43 μM. Further substitution in the compound 19 with an electron-donating methoxy group at the 3rd position of the phenyl ring of the sulphonamide group resulted in 20, which displayed ~6.31-fold activity loss with an IC₅₀ of 21.64 μM. This might be a result of the ability of the chloro group of 19 to grab electrons towards itself, which decreased the density and increased the positive charge of the π-electron cloud and thus facilitated its ability to interact with the stacked aromatic rings of the potential target protein 39.

Hybridisation of 4-acetamido-3-methoxybenzenesulfonyl chloride with 17a resulted in 21, which displayed ~3-fold improved antimalarial efficacy. The compounds 20 and 21 have similar benzene sulphonamide groups but have a structural difference at the 4th position of the quinazoline ring, resulting in a ~5-fold activity difference. This indicated that the 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine plays a significant role in defining the antimalarial efficacy of the compounds. A similar activity pattern was followed for compounds 25 and 28, which have identical sulphonamide groups but a structural difference at the 4th position of the quinazoline ring. The antimalarial efficacy of 25 with tetrahydrofurfurylamine group was ~2-fold better than 28 with 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine. Likewise, compound 27 with 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine was around 3-fold more potent than its analogue 24 with a tetrahydrofurfurylamine group at the 4th position. Another example of compound 34 revealed that 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine significantly improved the antimalarial efficacy, with an IC₅₀ value of 4.83 μM, as its analogue 33 with a tetrahydrofurfurylamine group displayed almost 3.8-fold lower antimalarial efficacy. Compounds 33 and 34 had an electron-withdrawing chloro group substituted on the thiophene ring of the sulphonamide group and showed micromolar activity against drug-sensitive malaria; however, the absence of the chloro group made both compounds inactive. Likewise, the significance of the positional substitution of NO₂ at the phenyl ring of the sulphonamide group related to the antimalarial efficacy was also noted. The substitution of the NO₂ group at the 2nd position of the benzene ring was found to be more fruitful than the substitution at the 4th position. Compounds 24 and 27 with the NO₂ group at the 2nd position of the phenyl ring displayed IC₅₀ values of 8.80 μM and 2.90 μM, respectively, while



Table 1 Structures and half-maximum inhibitory concentration (IC_{50}) of the test compounds **19–36** for *Pf3D7* strain

Compound	Molecular structure	IC_{50} for <i>Pf3D7</i> strain (μM)
13		>25
14a		8.26
14b		9.96
16		>25
17a		13.53

Table 1 (Contd.)

Compound	Molecular structure	IC_{50} for <i>Pf3D7</i> strain (μM)
17b		>25
General Structure of Compounds 19 – 36		
19		3.43
20		21.64
21		4.41
22		>25



Table 1 (Contd.)

Compound	Molecular structure	IC ₅₀ for <i>Pf</i> 3D7 strain (μM)
23		>25
24		17.82
25		3.51
26		>25
27		2.90
28		16.27
29		>25
30		19.26

Table 1 (Contd.)

Compound	Molecular structure	IC ₅₀ for <i>Pf</i> 3D7 strain (μM)
31		20.85
32		>25
33		16.35
34		16.08
35		>25
36		>25

their analogues with the NO₂ group at the 4th position were either inactive or less potent against the *Pf*3D7 strain. Thus, the SAR study emphasised that 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine played a significant role in the development of new antimalarials, and it was found fruitful when hybridised with quinazoline-sulphonamides.

The detailed SAR investigation revealed that the positional substitution of different electron-withdrawing groups on the phenyl ring of the sulphonamides was found to be significant to fine-tune the antiplasmodial efficacy of the compounds. Finally, our study highlights compounds 19 and 27 as potential leads for the development of a new class of antimalarials.

2.3. Effect of the lead compounds on the development and morphology of the parasites

Post-IC₉₀ estimation, the selected compounds were tested against various asexual stages of *Plasmodium falciparum* to



assess their effects on parasite morphology and development. Dimethyl sulfoxide (DMSO) was used as the solvent control throughout the experiment. Synchronised ring-stage parasites (6–16 hours post-invasion) were exposed to the compounds for 64 hours, and Giemsa-stained blood smears were examined microscopically at intervals of 6–16, 30–34, 44–48 hours, and again at 6–16 hours (Fig. 2).

In the DMSO-treated control group, parasites progressed normally through the intraerythrocytic developmental cycle, maturing from rings to trophozoites, then schizonts, and producing new ring-stage progeny. The images at different time intervals clearly indicate the formation of hemozoin crystals at a 30–34 h time interval, which is also observed later at 44–48 h. In the case of the test compounds treated parasites, no visible crystal was observed at any stage of the parasitic development. This phenomenon suggested that the compounds may target the parasite's hemozoin formation pathway, haeme detoxification pathway, and/or haemoglobin digestion pathway to show their antimalarial efficacy. In contrast, treatment with compound **14b** notably inhibited the transition from trophozoites to schizonts, leading to developmental arrest at the schizont stage, with a swollen effect on the parasite's food vacuole. Parasites exposed to compounds **14a**, **19**, and **25**

exhibited marked shrinkage within erythrocytes after 34 h of treatment, with complete developmental arrest at the ring stage and no further progression observed. Notably, compounds **21** and **27** induced developmental arrest at the trophozoite stage, characterised by a distinct swelling of the parasite's food vacuole, suggesting a potential disruption of vacuolar function. Literature suggests that inhibitors of parasitic aspartic proteases and cysteine proteases result in swollen food vacuoles.^{40,41} Therefore, the swelling effect on the parasite's food vacuole may correspond to the binding of the test compounds to aspartic proteases and/or cysteine proteases.

Collectively, these findings demonstrate that the six lead compounds exert stage-specific inhibitory effects on the asexual blood stages of *P. falciparum*. Further mechanistic studies and structural optimisation of these compounds hold promise for the development of potent, low-nanomolar antimalarial agents with diverse modes of action.

2.4. Cytotoxicity of the compounds

A549 lung carcinoma cell cultures were adopted to investigate the viability of the most potent compounds against the *Pf3D7* strain. The obtained results are reported in Table 2, which indicates that compound **27** is non-cytotoxic to the cancerous cell A549 and more selective towards parasitic cells, with a selective index of 66.72. Furthermore, compounds **19** and **21** were found to be toxic to some extent in cancerous cells and were selective towards parasitic cells, with a selective index of 19.45 and 17.26, respectively. Compound **14b** was found to be toxic to the cancerous cells with an IC_{50} value of 28.66 μ M and may be further optimised for the development of new anti-cancer agents.

Furthermore, cytotoxicity was also assessed using an MTT assay on activated macrophages derived from THP1 monocytes at 100 and 500 μ M concentrations of the compounds. The obtained results in Fig. 3 revealed that untreated cells grew normally.

The compound **19** displayed cell growth of 88.76% and 81.54% at 100 μ M and 500 μ M concentration, respectively, and compound **21** showed cell growth of 97.75% and 96.79% at 100 μ M and 500 μ M concentration, respectively. The results indicated that the test compounds displayed cell growth of more than 80% and may be considered non-toxic at selected




Fig. 2 Representative images of the morphology of test compounds treated parasites at different time intervals.

Table 2 Cytotoxicity evaluation of the compounds on lung cancer A549 cells^a

Compounds	A549 cells IC_{50} (μ M)	Selective index
14b	28.66 \pm 2.06	2.88
19	66.72 \pm 2.03	19.45
21	76.12 \pm 3.49	17.26
25	57.02 \pm 4.60	16.25
27	193.5 \pm 1.73	66.72

^a The results indicated are the averages of triplicate measurements. Selective index: IC_{50} value of cytotoxicity assay/ IC_{50} value of antimalarial assay.






Fig. 3 Effect of the test compounds on the growth of the activated macrophages from THP1 monocytes (the results were the average of the five independent experiments).

concentrations. Therefore, the antimalarial activity of the compounds was specific and not associated with cytotoxicity.

2.5. *In silico* studies

2.5.1. Docking studies. The growth development assay revealed that the active compounds displayed deformities in the food vacuole of the parasite, suggesting that the compounds may target the parasite's hemozoin formation pathway, haeme detoxification pathway, and/or haemoglobin digestion pathway to demonstrate their antimalarial efficacy. In the parasitic food vacuole, the haemoglobin is initially degraded by plasmepsins, histo-aspartic protease (HAP), and falcipains into 10–20 amino acid-long peptides.⁴² These large peptides further degrade by a zinc metalloprotease falcilysin into 5–10 amino acid oligopeptides, which further degrade into small peptides and amino acids.⁴² On the other hand, haemoglobin is converted into heme, which is further catalysed into hemozoin through heme detoxification protein (HDP) and other enzymes.⁴³ Therefore, to investigate the plausible mechanism of action, the molecules significantly effective at the parasitic food vacuole were docked with the selected *Plasmodium* food vacuole drug targets. The molecules were docked with *P. falciparum* cysteine proteases (falcipain II and III), aspartic proteases (plasmepsins I, II, IV, IX, and X), heme detoxification protein (HDP), histo-aspartic protease (HAP), and a zinc metalloprotease falcilysin (FLN). The coefficient of determination *R*-squared was calculated with the obtained docking score and experimental IC_{50} value, and the *R*-squared was found equal to or greater than 0.7 only with *P. falciparum* falcipain II (*PfFP2*), falcipain III (*PfFP3*), and falcilysin (*PfFLN*) as 0.7031, 0.8577, and 0.8977, respectively, Fig. S75. Therefore, the predicted IC_{50} was calculated using the equation of a straight line, followed by plotting the graph between the predicted and experimental IC_{50} values of the compounds. The

results were correlated with *R*-squared values of 0.7849, 0.8061, and 0.9267 for *PfFP2*, *PfFP3*, and *PfFLN*, respectively. Therefore, the protein–ligand interactions of the most potent molecules against *Pf3D7* strain, **19** and **27**, were investigated with the underlined proteins and are displayed in Fig. 4–6. The 2D protein–ligand interaction diagrams are accessible in Fig. S76–S81.

Falcipain II and III are hemoglobinases of the cysteine protease family,⁴⁴ which share a common catalytic mechanism involving a nucleophilic cysteine thiol in their catalytic triad to hydrolyse the haemoglobin at multiple sites in the food vacuole.^{45,46} Fig. 4 disclosed that **19** and **27** were tightly bound with *PfFP2* with docking scores of -5.2 and -5.7 , respectively. Fig. 4(a) revealed that ligand **19** interacted with *PfFP2* through a halogen bond between Cl and HIS174 with a bond length of 2.58 Å, and two aromatic H-bonds between the hydrogens of the quinazoline ring and ASP234 with a bond length of 2.50 and 2.69 Å. Similarly, ligand **27** was involved in making an H-bond acceptor between the N of the triazole group and HIS174 with a bond length of 2.79 Å, and a salt bridge between the NO_2 group of the ligand ASP234 with a bond length of 4.68 Å, Fig. 4(b). Furthermore, **19** and **27** were docked with *PfFP3* with docking scores of -5.3 and -6.1 , respectively (Fig. 5). The protein ligand interactions with *PfFP3* revealed that the NH group and the quinazoline ring of **19** were involved through a hydrogen bond and an aromatic hydrogen bond with GLY92, with the bond length of 1.85 Å and 2.30 Å, respectively, Fig. 5(a). There was no visible interaction observed in Maestro for **27** with *PfFP3*, Fig. 5(b).

Falcilysin (FLN) is a zinc-dependent metalloprotease belonging to the M16C family, playing a central role in haemoglobin breakdown within the parasite's digestive vacuole. It acts downstream of primary hemoglobinases such as falcipains,






Fig. 4 Protein ligand interactions of docked complexes of (a) **19** with *PffFP2* and (b) **27** with *Pf3FP2*.

plasmepsins, and HAP, processing the short peptide fragments they generate. The enzyme functions through a dynamic catalytic cycle: it initially opens to permit substrate entry into its spacious active site, then shifts into a closed conformation that facilitates peptide cleavage, and finally reopens to release the processed products.⁴⁷ Recent studies revealed that FLN is the target for the candidate drug MK-4815.⁴⁸ The ligands were docked at the MK-4815 binding site (allosteric site of FLN) and visualised to investigate the protein-ligand interactions, represented in Fig. 6.

Fig. 6 revealed that **19** and **27** were deeply seated in the groove of the *PffFLN* and strongly bound with the target protein. Ligand **19** was involved in making an H-bond through the NH group with ASP526, with a bond length of 2.08 Å, Fig. 6(a). Another H-bond was also observed between the oxygen of the acetamide group and ASN420, with the bond length of 2.30 Å. Additionally, two aromatic H-bonds were also observed between hydrogens of quinazoline ring and ASP526 and ASP451 with the bond length of 2.63 Å and 2.45 Å, respectively.

Similarly, ligand **27** was bound to the target protein with multiple interactions. Fig. 6(b) revealed that the quinazoline ring interacted with PHE545 through π - π stacking with the bond length of 5.16 Å. Furthermore, the SO₂ and NO₂ groups of

27 were interacted with ASN420 and ASN421 through H-bond with the bond length of 2.11 Å and 2.33 Å, respectively. The π -cation type of interaction was observed between the N⁺ of the NO₂ group and HIE425, with the bond length of 5.68 Å. Additionally, an aromatic H-bond was also observed between the hydrogens of the quinazoline ring and ASP526, with a bond length of 2.40 Å. The ligand binding results were consistent with the earlier studies of Eagon, *et al.*⁴⁹ and Kahlon, *et al.*⁵⁰

The docking studies revealed that the synthesised hybrid molecules may bind with the *PffFP2*, *PffFP3*, and *PffFLN* through significant protein-ligand interactions. In the case of docking, only the ligand is flexible, while the receptor is rigid; however, as the temperature changes, both become flexible. Therefore, the accuracy of the docking remains very limited; hence, to investigate the stability of these complexes, a molecular dynamics simulation study was performed on Desmond through Maestro of Schrödinger.

2.5.2. Molecular dynamics (MD) simulation. An explicit-solvent MD simulation for 200 ns at NPT and 310 K was performed to investigate the stability, behaviour, and interactions of protein-ligand complexes with respect to time and temperature. The apo forms of *PffFP2*, *PffFP3*, and *PffFLN*, as well as docked protein-ligand complexes with **19** and **27**, were subject






Fig. 5 Protein ligand interactions of docked complexes of (a) **19** with *PffFP3* and (b) **27** with *PfFP3*.

to simulation, which also revealed the orientation of the ligand within the protein's binding pocket. The docked complexes were immersed in the water molecules and neutralised by adding Na^+ and Cl^- ions before simulation.

2.5.2.1 Root-mean square deviation (RMSD). The RMSD trajectory of the apo form of *PffFP2* displayed initial stabilisation at ~ 1.2 Å and then a gradual increase toward 2.5 Å over the simulation time, suggesting conformational changes as the protein explores its dynamic states, Fig. S82(a). The same can also be observed in the simulation movie, Movie M1.

The RMSD trajectory of the *PffFP2-19* complex displayed initial conformational changes upon binding with the ligand, but was observed to be comparatively tight and stable, while the ligand RMSD trajectory fluctuates for a long stretch with two sharp spikes ~ 100 ns and ~ 150 ns, Fig. S82(b). This event indicated that ligand **19** keeps the protein more stable than the apo state, but the ligand itself explores multiple poses, higher-deviation transitions, which reveal more dynamic binding.⁵¹ Moreover, the protein RMSD trajectory of the *PffFP2-27* complex rises steadily and stays high and peaks at ~ 4.0 Å late in the run, but the ligand RMSD remains lower compared to the **19**, with

occasional spikes, indicating a persistent pose with moderate jitter. The RMSD trajectory of the ligand in *PffFP2-27* complex, Fig. S82(c), revealed that **27** binds to the protein in a more self-consistent pose, but it induced larger global rearrangements of the protein as compared to the apo form or complex with **19**. Hence, ligand **19** develops a complex with good stability, while ligand **27** increases backbone deviation in the protein, suggesting broader conformational adaptation. The confirmations of *PffFP2-19* and *PffFP2-27* complexes and ligand-protein interaction events during the simulation may also be observed in simulation movies, Movies M2 and M3, respectively.

The RMSD trajectory for the apo form of *PffFP3*, Fig. S83(a), displayed a quick rise in the earliest frames to ~ 1.6 – 1.9 Å by ~ 20 – 40 ns, then drifts upward slowly and stabilises roughly between ~ 1.8 – 2.4 Å up to 200 ns. This trend indicates gradual relaxation from the starting (crystal) conformation to a slightly shifted but compact ensemble. The RMSD trajectory of *PffFP3-19* complex in Fig. S83(b) displayed that the protein initially follows a similar pattern as the apo form, but exhibits slightly higher average values, ~ 2.0 – 2.7 Å, between ~ 40 – 140 ns and stabilises throughout the simulation. The increase in RMSD






Fig. 6 Protein ligand interactions of docked complexes of (a) **19** with *PfFLN* and (b) **27** with *Pf3FLN*.

may be due to the ligand-induced conformational changes in the protein. The RMSD trajectory of the ligand **19** displayed low-to-moderate fluctuations up to ~ 80 ns, then stabilised for the rest of the simulation with a sharp spike at ~ 120 ns. This trajectory pattern suggests the ligand reorientation events and partial displacement from the initial pose. These conformational changes and ligand behaviour of the apo protein and in complex with **19** during the simulation may also be observed from the simulation movies, Movies M4 and M5, respectively. The RMSD trajectory pattern of *PfFP3-27* complex revealed that the protein RMSD displayed a quicker rise at ~ 20 ns than at ~ 50 ns, which was overall larger than the apo form or in the complex with **19**, Fig. S83(c). That indicates a more pronounced backbone rearrangement during the run.⁵² The ligand RMSD for **27** remains relatively low early on, but after ~ 100 ns, it increases substantially and becomes highly variable, reaching very large values (double-digit Å in late frames), which strongly suggests the ligand underwent a major displacement and partially relocated in the original binding site, also confirmed by the simulation movie, Movie M6. The RMSD results of apo *PfFP3* and its complexes revealed that the experimental crystal structure relaxes to a stable solution ensemble with modest

conformational drift over 200 ns. For complexes, **19** is likely a moderately stable binder with multiple binding microstates, which keeps the protein closer to its apo state compared to **27**. This may be due to the fewer tight contacts that remain associated with the protein. The RMSD results for ligand **27** suggest that (i) its interactions may require larger protein rearrangement (induced fit) but ultimately are not stable or lead to ligand escape, (ii) the ligand initially finds an alternate pocket that perturbs backbone geometry, and later the complex relaxes to an alternative state with the ligand shifted away.^{34,53} Both cases imply strong local dynamics and a binding mode that is not rigidly conserved over 200 ns.

Furthermore, the RMSD trajectory of the apo form of *PfFLN* displayed a stable RMSD during the first 50 ns, followed by a progressive rise, reaching values of ~ 2.5 – 3.5 Å after ~ 100 ns and maintaining fluctuations around this range until the end of the simulation, Fig. S84(a) and Movie M7. These fluctuations suggest that *PfFLN* undergoes significant conformational rearrangements in the apo state, likely linked to its intrinsic flexibility as a metalloprotease.^{54,55} The RMSD trajectory of protein in complex with **19** displayed an early rise and reached equilibrium at ~ 30 ns, which remains lower than the apo trajectory,



with average backbone RMSD in the ~ 1.8 – 2.2 Å range after equilibration, Fig. S84(b). The ligand RMSD was also relatively small and well-behaved (~ 1.3 – 1.8 Å), indicating that ligand **19** retains a consistent binding pose for most of the simulation, Movie M8. In Fig. S84(c) of complex *PfFLN*-**27**, the protein RMSD was intermediate to high, typically ~ 1.8 – 2.5 Å, but with several transient excursions beyond 2.5 Å later in the run. The ligand **27** exhibits wider fluctuations in RMSD, ranging from ~ 1.2 to 3.5 Å, including episodes of larger deviation late in the trajectory. The combined behaviour suggests a period of induced conformational adjustment followed by increased ligand mobility. The **19** complex reaches a plateau within ~ 30 ns and remains near that plateau, consistent with rapid local relaxation and a stable ligand–protein complex. The **27** complex displays a two-phase behaviour: an initial relaxation and induced fit (0–100 ns) accompanied by modest protein rearrangements, followed by increased ligand mobility and several ligand deviation events after ~ 120 ns. These deviations are temporally coincident with transient increases in protein RMSD, suggesting coupled ligand–protein rearrangements. These events can also be confirmed by the simulation movie, Movie M9.

The comparative analysis demonstrates that both ligands exhibit strong binding affinity toward the target proteins, with greater structural stability observed in the complex with *PfFLN* relative to *PfFP2* and *PfFP3*. The RMSD profiles predicted that *PfFLN* may be the principal target implicated in the antimalarial potential of these ligands, while the concurrent inhibition of *PfFP2* and *PfFP3* may provide a complementary or synergistic contribution to their overall efficacy.

2.5.2.2 Root mean square fluctuation (RMSF). Root mean square fluctuation (RMSF) is useful for characterising local changes along the protein chain. The RMSF plot of the apo proteins and their complexes provides clear insights into the protein's conformational flexibility, ligand effects, and implications for drug design.

The RMSF plot of apo *PfFP2* in Fig. S85(a) shows higher peaks and relatively higher residue fluctuation, especially in loop regions, compared to both ligand-bound complexes. Fig. S85(b) and S85(c) revealed that the binding of ligands **19** and **27** affected the protein's residue fluctuations and resulted in a decrease in fluctuations, which indicates the stabilisation of the protein by ligand binding. The plot highlighted that **27** induced stronger stabilisation, as confirmed by the lower RMSF in most of the regions, while **19** retained moderate flexibility, which may correspond to exposed or mobile loop areas. In both cases, the profile for $C\alpha$ and backbone atoms was very similar, supporting that stabilisation was global, but most pronounced near the ligand-binding regions. The vertical green bars indicate ligand contact with protein residues during the simulation. The RMSF results for the apo form of *PfFP3* and its complexes with **19** and **27** were shown in Fig. S86.

Fig. S86(a) revealed that apo falcipain-3 exhibited higher RMSF values at both N- and C-terminal ends and several loop regions, indicating greater intrinsic flexibility where no ligand is bound. When ligand **19** was bound to the falcipain-3, Fig. S86(b), the residue stretches were greatly affected. The vertical green bar indicated that the residues of these regions

were involved in making non-covalent interactions, and fluctuations highlighted that the protein–ligand complex is changing conformational state to get a lower energy state. Fig. S86(c) indicates that ligand **27** exhibits fewer protein–ligand contacts compared to ligand **19**, but stabilises more residual fluctuation (residues 75–90) than the apo form complex with ligand **19**. Residues outside the ligand contact zones retain their flexibility, like the apo protein. Differences between the ligands (**19** vs. **27**) in the extent and location of stabilisation may be attributed to their distinct binding modes, chemical structures, and interaction networks within the falcipain-3 active or allosteric sites. Ligand **19**, showing a broader interaction footprint than ligand **27**, potentially translates to enhanced inhibitory potential. The RMSF analysis results of falcipain in apo form and in complex with ligands **19** and **27** were presented in Fig. S87.

The RMSF plot of the apo protein, Fig. S87(a), displayed several distinct peaks with higher flexibility in multiple residue regions. Peaks likely correspond to loops or surface regions, which are generally more mobile in the absence of ligands. The average RMSF is higher across the range compared to the complexes. Fig. S87(b) and S87(c) indicate that the binding of ligands **19** and **27** noticeably reduces the RMSF values in multiple regions, especially at the ligand binding sites, highlighted using green vertical bars. The RMSF data highlighted that interacting residues are tightly associated with the ligand, resulting in noticeable stabilisation and lower atomic displacement at and near the ligand binding sites. Few peaks remain in the complex plots, but their intensities have been reduced compared to the apo form, which suggests effective ligand-induced rigidification.

The RMSF data for the apo and complex forms of all three target proteins revealed that both ligands induced local stabilisation at their respective binding sites, reducing RMSF values of associated amino acid residues, which is consistent with classical MD simulation interpretations where ligand binding restricts atomic displacements and conformational freedom locally.^{56,57} The higher fluctuation profile of the apo form of the proteins highlights larger conformation sampling and flexibility, which is also needed for substrate recognition, which decreases upon binding with the ligands.^{58,59} Both ligands, **19** and **27**, display similar stabilising trends, though the specific residues affected and the degree of rigidity differ, which may reflect differing binding poses, interaction strengths, or allosteric effects. The lower RMSF fluctuations in complexes are generally defined as evidence of stable binding and limited flexibility at interacting residues, while higher flexibility refers to the inherent protein flexibility not modulated by ligand attachment.^{60,61} Hence, the RMSF trends were in correlation with the RMSD data and supported our hypothesis that the antimalarial activity of the ligands may be due to the inhibition of cysteine proteases and falcipain.

2.5.2.3 Protein–ligand contacts study. The type and number of interactions between the target protein and the ligand can be monitored throughout the MD simulation. These interactions can be divided into different categories, such as hydrogen bonds, hydrophobic, ionic and water bridges, *etc.* Hydrogen



bonds are further characterised into four sub-parts, *i.e.* backbone acceptor, backbone donor, side-chain acceptor, and side-chain donor. Similarly, halogen atoms can form attractive interactions by functioning as both electron donor and acceptor sites and can play an important role in ligand specificity. Likewise, hydrophobic interactions can be categorised into three sub-categories, *i.e.* π -cation, π - π interaction, and other non-specific interactions. Traditionally, these types of interactions are formed between a hydrophobic amino acid and an aromatic or aliphatic group on the ligand. Moreover, ionic interactions are formed between two oppositely charged atoms, and water bridges are considered in MD simulations as hydrogen-bonded protein–ligand interactions mediated by a water molecule.

Fig. 7 revealed that most of the ligands exhibited significant protein–ligand interactions during the course of simulation. Fig. 7(a) and S88 disclosed that ligand **19** was involved with *Pf*FP2 mainly through hydrophobic interaction *via* LEU84 for more than 35% of simulation time, and water bridge, hydrogen bond *via* LEU172 and ASN173. Similarly, ligand **19** was involved with *Pf*FP3 through multiple hydrogen bonds and hydrophobic interactions. Fig. 7(b) and S90 displayed that TYR93 was involved with the ligand through π - π interaction and hydrogen bond for 34% and 50% of simulation time, respectively. ASN86 also displayed a hydrogen bond with the ligand **19** for 44% of simulation time. Protein–ligand contact analysis displayed strong binding between *Pf*FLN and **19**, as shown in Fig. 7(c) and S92. The amino acid residues ASN420 and ASN421 were involved in making a hydrogen bond for 98% and 90% of the simulation time, respectively. TYR413 and GLU530 displayed interaction through a water bridge for 44% and 63% of simulation time, respectively.

The study of protein–ligand interaction of ligand **27** disclosed multiple interactions with the target protein throughout the simulation. It was involved with *Pf*FP2 mainly through three hydrogen bonds with GLN36, CYS42, and ILE85 for 64%, 81%, and 88% of simulation time, respectively, as shown in Fig. 7(d) and S89. Ligand **27** was contacted with *Pf*FP3 mainly through TRP215 *via* π - π interaction for 53% of simulation time, as indicated in Fig. 7(e) and S91. Similar to ligand **19**, ligand **27** was also strongly bound to *Pf*FLN through hydrogen bonds and hydrophobic interactions. Fig. 7(f) and S93 disclosed that residues ASN420 and ASN421 of *Pf*FLN were involved in making hydrogen bonds with 86% and 43%, respectively. Furthermore, PHE529 was involved in making π - π interactions with **27** for 39% of simulation time, along with other hydrophobic interactions. The higher length of bars in the protein–ligand histogram for ASN420, ASN421, and PHE529 is due to the multiple interactions of a single type of residue with the same ligand.

The results of the protein–ligand contact study for all six complexes showed close proximity, as indicated by RMSD and RMSF values. *In silico* studies predicted that all ligands were tightly bound to *Pf*FLN, as well as to *Pf*FP2 and *Pf*FP3. Hence, it suggests that the associated antimalarial efficacy may be due to the inhibition of these proteins.

2.5.3. Molecular mechanics-generalised born surface area (MM-GBSA). MM-GBSA (molecular mechanics/generalised born surface area) is a widely used computational approach in drug discovery that provides an estimate of the free energy of ligand–protein binding. This method combines molecular mechanics energies with implicit solvation models, using the generalised born approximation for electrostatics and a surface area term for nonpolar solvation contributions, to achieve more reliable binding affinity predictions than conventional docking scores.




Fig. 7 2D representation of protein–ligand contacts during 200 ns MD simulations. (a) *Pf*FP2-**19**, (b) *Pf*FP3-**19**, (c) *Pf*FLN-**19**, (d) *Pf*FP2-**27**, (e) *Pf*FP3-**27**, and (f) *Pf*FLN-**27** complexes.



Table 3 Post-MD MM-GBSA binding free energies (kcal mol⁻¹) for PjFP2, PjFP3, and PjFLN in complex with ligands **19** and **27**

Complex	ΔG average (kcal mol ⁻¹)	Standard deviation
PjFP2- 19	-48.2992	±6.10
PjFP2- 27	-59.7697	±5.39
PjFP3- 19	-54.7571	±10.17
PjFP3- 27	-56.8884	±5.70
PjFLN- 19	-50.3223	±4.55
PjFLN- 27	-51.5066	±4.73

To obtain binding free energies under dynamic conditions, the molecular dynamics (MD) trajectories of all six protein–ligand complexes were subjected to post-MD MM-GBSA calculations. The results are summarised in Table 3.

The post-MD MM-GBSA analysis confirmed stable binding of both ligands with their respective target proteins. Among the complexes, PjFLN exhibited the lowest standard deviations in binding free energy, suggesting that ligand interactions with PjFLN were more consistent throughout the simulation when compared to PjFP2 and PjFP3. Taken together, these *in silico* findings predict that the observed antimalarial activity of ligands **19** and **27** may be mediated through the plausible inhibition of PjFLN in addition to PjFP2 and PjFP3. To validate the *in silico* predictions, future *in vitro* enzymatic assays would be essential to provide deeper and clearer mechanistic insight into their mode of action. The ADME predictions and physico-chemical properties of the synthesised compounds have been discussed in the SI and Table S1.

3. Conclusion

To combat the resistance to the current antimalarials, there is a challenge and an urgent need for the development of new antimalarials with a novel mode of action. The present study aimed to develop quinazoline-based trifunctional hybrid antimalarials with potential antimalarial activity. Bioactive small pharmacophores such as 2,4-dichloroquinazoline, tetrahydrofurfurylamine, substituted sulfonamides, and triazolo [4,3-*a*]pyrazine were utilised to construct a new class of antimalarials. Results revealed that most quinazoline sulphonamide hybrids were shown to be potential antimalarials, with an IC₅₀ value below 10 μM for the drug-sensitive Pj3D7 strain. The results revealed that molecular hybrid **27**, with 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine at the 4th position and substituted sulphonamides at the 2nd position of quinazoline, was the most potent against the Pj3D7 strain with an IC₅₀ value of 2.9 μM. Moreover, hybrid **19**, with tetrahydrofurfurylamine at the 4th position and substituted sulphonamides at the 2nd position of quinazoline, was the second most potent compound against the Pj3D7 strain with an IC₅₀ value of 3.4 μM. The MTT assay was performed on A549 lung cancer cells and activated macrophages derived from THP-1 monocytes to assess the associated cytotoxicity of the compounds. The results against A549 cells disclosed that **19** and **27** were more selective towards parasitic cells, with the selective index of 19.45 and 66.72, respectively. The compounds

14b, **24**, and **28** were moderately cytotoxic to the cancerous cells and may be further developed as potential anticancer agents. The results against THP1 cells revealed that the cell growth was more than 90% on treatment with 100 μM concentration of the test compounds, except **19**, which displayed 88.76% cell growth. Therefore, the results indicated that the antimalarial activity of the compounds was specific and not associated with cytotoxicity. The *in silico* studies, *i.e.* docking followed by MD simulation and MM-GBSA analysis, were conducted to computationally predict the plausible mechanism of action of the potent molecules. The *in silico* predictions suggested that the antimalarial efficacy of the compounds may be attributed to the plausible inhibition of zinc metalloprotease PjFLN, with concurrent inhibition of cysteine proteases PjFP2 and PjFP3, which require further validation through enzymatic assays. The calculated and predicted physico-chemical parameters of the compounds fall within the Schrödinger range, which is relied on by 95% of all known medications. The study addressed the significance of the molecular hybridisation approach for the identification of an entirely distinct class of antimalarials. Compounds **19** and **27** were thus highlighted in the study as striking molecules that could be further optimised for the development of new antimalarials.

4. Method and materials

4.1. Chemistry

All chemicals and reagents were purchased in AR grade from commercial suppliers and used without further purification. Substituted anilines, acyl chloride, chlorosulphonic acid, anhydrous piperazine, morpholine, and acetophenone were procured from Spectrochem Pvt. Ltd, India. Hünig's base *N,N*-diisopropylethylamine (DIPEA) was procured from Sisco Research Laboratories Pvt. Ltd, India. Methyl anthranilate and tetrahydrofurfurylamine were procured from Alfa-Aesar, USA. Urea and EtOH were obtained from Merck Millipore, India, and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine, HCl was obtained from BLD Pharmatech (India) Pvt. Ltd, India. Different sulphonyl chlorides were procured from TCI Chemicals (India) Pvt. Ltd, India. Solvents such as *N,N*-dimethylformamide (DMF), dichloromethane (DCM), and tetrahydrofuran (THF) were anhydrous and procured from Spectrochem Pvt. Ltd, India. The ¹H & ¹³C NMR spectral data were recorded with a Bruker Avance Neo 400 NMR spectrometer. Tetramethylsilane (TMS) was used as an internal standard, and the observed chemical shift (δ) value was marked in ppm. The multiplicity of ¹H NMR signals was labelled as s (singlet), d (doublet), t (triplet), m (multiplets), q (quartet), p (pentet), dd (double doublets), td (triplet of doublets), dt (doublet of triplets), dq (doublet of quartets), qd (quartet of doublets), tt (triplet of triplets), qt (quartet of triplets), dtd (doublet of triplet of doublets), ddd (doublet of doublet of doublets). HRMS spectra of the compounds were calculated with an Agilent G6530AA (LC-HRMS-Q-TOF). Silica gel-coated aluminium plates, TLC Silica gel 60 F254 of Merck Millipore, were used for conducting analytical thin-layer chromatography (TLC) experiments and visualised under a UV-chamber equipped with long-wavelength (365 nm) and short-wavelength (254 nm). The silica gel of 200–400 mesh was procured from Sisco Research Laboratories Pvt. Ltd, India, and



used for column chromatography. Chloroquine-resistant *P. falciparum* 3D7 strain was obtained from the Malaria Research and Reference Reagent Resource Center (MR4). Human blood was used from *P. falciparum* culture in this study. Donor blood was obtained from Rotary Blood Bank (RBB), New Delhi, India. RBB is an ISO 9001:2008 certified blood bank established in 2002. It follows stringent screening procedures, careful documentation, and good laboratory practices for collecting, processing, and testing blood. Albumax was obtained from Gibco, New Zealand and RPMI media from Invitrogen, India. Chloroquine, Molecular Biology Grade DMSO, tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], sorbitol, and Phorbol 12-Myristate 13-Acetate (PMA) were obtained from Sigma-Aldrich. SYBR Green dye was obtained from Invitrogen, India. Lung cancer A549 epithelial cells and THP1 monocytes were obtained from ATCC. Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco, USA. RPMI-1640 medium was obtained from Cellclone, India.

4.1.1. General synthetic protocol for 4-acetamidobenzene-1-sulfonyl chlorides (5a–5b) and 3-acetylbenzenesulfonyl chloride (7). The 4-acetamidobenzene-1-sulfonyl chlorides (5a–5b) were synthesised by following the previously reported protocol of Manzoor, *et al.*,⁶² Scheme 1. For detail, substituted anilines (8.2 mmol) and Et₃N (12.3 mmol) were dissolved in anhydrous DCM at room temperature and stirred for 0.5 h. To the solution, acyl chloride (10.25 mmol) was added in a dropwise fashion, followed by continuous stirring at 0 °C for 0.5 h. The temperature was allowed to rise to room temperature and stirred for 1.5 h till the completion of the reaction. The organic phase was extracted using DCM and dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain *N*-phenylacetamide (3a–3b) and used for the next step.

Chlorosulfonic acid (15.756 mmol) was added in a dropwise fashion to the respective *N*-phenylacetamide (3a–3b) (3.03 mmol) in a round-bottom flask equipped with a magnetic bar at 0 °C, followed by stirring for 0.25 h. The resulting mixture was heated to the optimal temperature and stirred by almost all gas evolution was completed (10 °C/0.5 h for 5a; 60 °C/4 h for 5b). After the reaction was complete, the mixture was cooled and quenched with crushed ice in a beaker while being vigorously stirred to free any associated sulfonyl chlorides from the beaker's walls. The precipitate was filtered and washed with ice-cold water and purified using column chromatography to afford 4-acetamidobenzene-1-sulfonyl chlorides (5a–5b) in 75–85% yield. A similar protocol was followed to afford 3-acetylbenzenesulfonyl chloride (7) with some modifications, Scheme 2. On addition of sulphonyl chloride to acetophenone, the resulting mixture was heated at 90 °C for 12 h, followed by quenching and purification. Purified products 5a–5b and 7 were used for the next steps.

4.1.2. General synthetic protocol for 2,4-dichloroquinazoline (11). The compound 2,4-dichloroquinazoline 11 was obtained by following the synthetic protocol of Hu, *et al.*⁶³ with some modifications, Scheme 3. In a 250 ml round-bottom flask, methyl anthranilate (33.076 mmol) was mixed with urea (82.690 mmol) and stirred at 200 °C for 2 h. The clear, melted mixture was formed, which was converted into the solid,

cooled at room temperature, and washed with ice-cold water, followed by cool ethyl acetate to remove unreacted urea and methyl anthranilate. A white solid was obtained and dried at 45 °C overnight. The dried solid (5 gm) was added to the mixture of POCl₃ (80 ml) and DIPEA (10 ml) with continuous stirring and heated at 90 °C for 6 h. The reaction mixture was allowed to cool overnight and quenched with crushed ice under vigorous stirring. The solid was filtered and washed with ice-cold water, followed by purification by column chromatography using silica as a solid phase and hexane:EtOAc (80:20) as the mobile phase. The solvent was removed under reduced pressure, and 2,4-dichloroquinazoline (11) was obtained as a white solid. Yield = ~90%.

4.1.3. General synthetic protocol for 2-chloro-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (13) and 2-chloro-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (16). In a round-bottom flask, 2,4-dichloroquinazoline (11, 10.05 mmol) was added to the solution of tetrahydrofurfurylamine (10.55 mmol) and Et₃N (15.83 mmol) in anhydrous THF and stirred for 1 h at 60 °C, Scheme 4. On completion of the reaction, the organic phase was extracted with EtOAc and washed with water, followed by brine, and dried over anhydrous Na₂SO₄. The final product was purified with column chromatography, taking silica gel (200–400) as the stationary phase and hexane:EtOAc (40:60) as the mobile phase. The solvent was evaporated under vacuum to afford product 2-chloro-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (13) as a white solid. Yield = 99%. ¹H NMR (400 MHz, chloroform-*d*) δ 7.66–7.57 (m, 3H), 7.32 (ddd, *J* = 13.2, 8.4, 4.8 Hz, 1H), 6.60 (t, *J* = 5.2 Hz, 1H), 4.22–4.11 (m, 1H), 3.97 (ddd, *J* = 16.8, 6.4, 3.2 Hz, 1H), 3.88 (dt, *J* = 8.4, 6.8 Hz, 1H), 3.82–3.72 (m, 1H), 3.39 (ddd, *J* = 13.6, 8.4, 4.4 Hz, 1H), 2.10–2.00 (m, 1H), 1.95–1.86 (m, 2H), 1.59 (dq, *J* = 12.0, 7.2 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 161.0, 157.5, 150.7, 133.5, 127.6, 126.1, 121.0, 113.2, 77.2, 68.2, 45.3, 28.9, 25.9. ESI HRMS, found 264.0898 (C₁₃H₁₄ClN₃O, [M + H]⁺ requires 264.0898).

Similar protocol was followed to synthesize 2-chloro-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (16). 2,4-dichloroquinazoline (11, 5.03 mmol) was added to the solution of 3-(Trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-*a*]pyrazine, HCl (5.28 mmol) and KOH (11.61 mmol) in anhydrous THF (25 ml) and stirred for 4 h at 40 °C, Scheme 5. The desired product 16 was afforded as an off-white solid. Yield = 95%. ¹H NMR (400 MHz, chloroform-*d*) δ 7.92 (ddd, *J* = 8.4, 5.6, 1.2 Hz, 2H), 7.88–7.81 (m, 1H), 7.59 (ddd, *J* = 10.0, 7.2, 1.6 Hz, 1H), 5.33 (s, 2H), 4.52 (t, *J* = 5.6 Hz, 2H), 4.31 (t, *J* = 5.2 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 165.0, 155.8, 153.5, 143.9 (q, *J* = 38.88 Hz, 1C), 149.88, 134.43, 128.64, 126.85, 124.07, 118.3 (q, *J* = 270.28 Hz, 1C), 114.41, 47.39, 45.15, 42.63. ESI HRMS, found 355.0678 (C₁₄H₁₀ClF₃N₆, [M + H]⁺ requires 355.0681).

4.1.4. General synthetic protocol for substituted *N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (14a–14b). To the solution of piperazine (9.50 mmol) and K₂CO₃ (14.25 mmol) in anhydrous DMF (25 ml), 2-chloro-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (13, 1.90 mmol) was added in portions and stirred at 90 °C for 12 h, Scheme 4. The reaction



mixture was allowed to cool, and the organic phase was extracted with DCM, washed with water, and dried over anhydrous Na₂SO₄. The final product was purified with column chromatography, taking silica gel (200–400) as the stationary phase and CHCl₃:MeOH (80:20) as the mobile phase. The solvent was evaporated under a vacuum to afford product **14a** in an off-white molten state, and it solidified at room temperature. The piperazine was replaced with morpholine (3.80 mmol) by following a similar protocol to afford the desired product **14b** as an off-white solid product, Scheme 4.

4.1.4.1 2-(Piperazin-1-yl)-N-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (14a). Yield = ~95%. ¹H NMR (400 MHz, chloroform-*d*) δ 7.61–7.50 (m, 2H), 7.47 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.12 (ddd, *J* = 9.6, 6.8, 1.6 Hz, 1H), 6.14 (t, *J* = 5.6 Hz, 1H), 4.17 (qd, *J* = 7.2, 3.6 Hz, 1H), 4.11 (t, *J* = 5.2 Hz, 4H), 3.98–3.88 (m, 2H), 3.87–3.77 (m, 1H), 3.52 (ddd, *J* = 16.0, 8.8, 4.0 Hz, 1H), 3.16 (t, *J* = 5.2 Hz, 4H), 2.10–2.02 (m, 1H), 2.00 (t, *J* = 5.2 Hz, 2H), 1.94 (q, *J* = 8.0 Hz, 1H), 1.75–1.60 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 177.66, 160.19, 158.24, 151.55, 132.79, 125.82, 121.75, 121.01, 110.69, 68.22, 44.71, 44.05, 43.69, 42.12, 28.93, 25.92, 23.15. ESI HRMS, found 314.1975 (C₁₇H₂₃N₅O, [M + H]⁺ requires 314.1976).

4.1.4.2 2-Morpholino-N-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (14b). Yield = ~95%. ¹H NMR (400 MHz, chloroform-*d*) δ 7.58–7.52 (m, 1H), 7.51–7.40 (m, 2H), 7.03 (ddd, *J* = 10.0, 6.4, 2.0 Hz, 1H), 6.44 (s, 1H), 4.11 (qd, *J* = 7.2, 3.6 Hz, 1H), 3.90–3.84 (m, 1H), 3.82 (dd, *J* = 6.4, 4.8 Hz, 4H), 3.79–3.74 (m, 2H), 3.74–3.70 (m, 4H), 3.48 (ddd, *J* = 13.6, 7.2, 4.8 Hz, 1H), 2.02–1.93 (m, 1H), 1.92–1.82 (m, 2H), 1.67–1.54 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 159.91, 157.75, 132.92 (2C), 124.57, 121.81, 121.34, 110.48, 77.37, 68.22, 67.00 (2C), 44.79, 44.73 (2C), 28.98, 25.88. ESI HRMS, found 315.1817 (C₁₇H₂₂N₄O₂, [M + H]⁺ requires 315.1816).

4.1.5. General synthetic protocol for substituted 4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline 17 (a–b). To the solution of piperazine (9.50 mmol) and Et₃N (14.25 mmol) in ACS grade EtOH (25 ml), 2-chloro-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**16**, 1.90 mmol) was added in portion and stirred and 80 °C for 14 h, Scheme 5. The reaction mixture was allowed to cool, and the organic phase was extracted with DCM, washed with water, and dried over anhydrous Na₂SO₄. The final product was purified with column chromatography, taking silica gel (200–400) as the stationary phase and CHCl₃:MeOH (50:50) as the mobile phase. The solvent was evaporated under a vacuum to afford product **17a** as a white solid. The piperazine was replaced with morpholine (3.80 mmol) by following a similar protocol to afford the desired product **17b** as a white solid.

4.1.5.1 2-(Piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (17a). Yield = ~98%. ¹H NMR (400 MHz, chloroform-*d*) δ 7.62 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.59–7.47 (m, 2H), 7.11 (ddd, *J* = 10.0, 6.4, 1.6 Hz, 1H), 4.98 (s, 2H), 4.32 (t, *J* = 5.6 Hz, 2H), 4.04 (t, *J* = 5.2 Hz, 2H), 3.79 (dd, *J* = 6.0, 4.4 Hz, 4H), 3.71 (dd, *J* = 6.0, 2.8 Hz, 4H), 1.43 (d, *J* = 202.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 164.71, 157.78, 154.48, 151.22, 143.6 (q, *J* = 39.19 Hz, 1C), 133.52,

126.83, 123.90, 121.95, 118.5 (q, *J* = 266.135 Hz, 1C), 111.45, 66.90 (2C), 46.90, 46.18, 44.50 (2C), 43.13. ESI HRMS, found 405.1758 (C₁₈H₁₉F₃N₈, [M + H]⁺ requires 405.1758).

4.1.5.2 4-(4-(3-(Trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazolin-2-yl)morpholine (17b). Yield = ~93%. ¹H NMR (400 MHz, chloroform-*d*) δ 7.63 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.58–7.47 (m, 2H), 7.12 (ddd, *J* = 9.6, 6.4, 1.2 Hz, 1H), 4.99 (s, 2H), 4.33 (t, *J* = 5.2 Hz, 2H), 4.05 (t, *J* = 5.6 Hz, 2H), 3.94 (t, *J* = 5.2 Hz, 4H), 3.02 (t, *J* = 5.2 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 177.37, 164.79, 157.39, 154.39, 151.18, 143.6 (q, *J* = 34.04 Hz, 1C), 133.59, 126.87, 123.89, 122.15, 118.35 (q, *J* = 264.11 Hz, 1C), 111.44, 63.69, 46.88, 46.19, 44.26, 43.10, 22.86. ESI HRMS, found 406.1602 (C₁₈H₁₈F₃N₇O, [M + H]⁺ requires 406.1598).

4.1.6. General synthetic protocol for substituted quinazoline-sulphonamides 19–36. To the 50 ml round bottom flask equipped with a magnetic bar, substituted benzene-1-sulfonyl chlorides (1.87 mmol) were treated with **14a** or **17a** (1.87 mmol) and K₂CO₃ (2.25 mmol) in anhydrous DMF and stirred for 3.5 h at 70 °C, Scheme 6. The desired product was extracted with EtOAc and washed with water, followed by brine, and dried over anhydrous Na₂SO₄. The crude was purified with column chromatography using silica gel (200–400) as the stationary phase and hexane:EtOAc (40:60) as the mobile phase. The solvent was evaporated under a vacuum to afford the final product as a solid.

4.1.6.1 N-(2-Chloro-4-(((4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazolin-2-yl)piperazin-1-yl)sulfonyl)phenyl)acetamide (19). 4-Acetamido-3-chlorobenzenesulfonyl chloride (**5b**) was treated with 2-(piperazin-1-yl)-N-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**14a**) and K₂CO₃ in anhydrous DMF to afford **19** as a white solid. Yield = 90%. ¹H NMR (400 MHz, chloroform-*d*) δ 8.53 (d, *J* = 8.8 Hz, 1H), 7.74–7.68 (m, 2H), 7.57 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.49–7.40 (m, 2H), 7.36 (d, *J* = 8.4 Hz, 1H), 7.01 (ddd, *J* = 9.2, 6.8, 1.2 Hz, 1H), 6.06 (s, 1H), 4.08 (qd, *J* = 7.2, 3.2 Hz, 1H), 3.95 (dd, *J* = 6.4, 4.4 Hz, 3H), 3.85 (dt, *J* = 8.4, 6.4 Hz, 2H), 3.80–3.69 (m, 1H), 3.66 (s, 1H), 3.42 (ddd, *J* = 13.6, 7.2, 4.4 Hz, 1H), 3.01 (t, *J* = 5.2 Hz, 4H), 2.19 (s, 3H), 2.02–1.92 (m, 1H), 1.87 (p, *J* = 6.4 Hz, 2H), 1.65–1.51 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 175.41, 168.54, 160.09, 157.96, 151.35, 138.62, 132.82, 130.77, 128.43, 127.58, 125.53, 122.45, 121.65, 121.00, 120.84, 110.55, 68.22, 63.70, 46.13, 44.67, 43.27, 28.91, 25.90, 25.04, 20.92. ESI HRMS, found 545.1730 (C₂₅H₂₉ClN₆O₄S, [M + H]⁺ requires 545.1733).

4.1.6.2 N-(2-Methoxy-4-(((4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazolin-2-yl)piperazin-1-yl)sulfonyl)phenyl)acetamide (20). 4-Acetamido-3-methoxybenzenesulfonyl chloride (**5a**) was treated with 2-(piperazin-1-yl)-N-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**14a**) and K₂CO₃ in anhydrous DMF to afford **20** as a white solid. Yield = 90%. ¹H NMR (400 MHz, chloroform-*d*) δ 8.80 (d, *J* = 2.0 Hz, 1H), 7.77 (s, 1H), 7.49 (ddd, *J* = 9.6, 3.2, 2.0 Hz, 4H), 7.10–7.02 (m, 1H), 6.92 (d, *J* = 8.8 Hz, 1H), 5.96 (s, 1H), 4.15 (qd, *J* = 7.2, 3.2 Hz, 1H), 4.01 (t, *J* = 5.2 Hz, 4H), 3.93 (s, 3H), 3.91–3.76 (m, 3H), 3.46 (ddd, *J* = 13.6, 7.6, 4.4 Hz, 1H), 3.10 (t, *J* = 5.2 Hz, 4H), 2.20 (s, 3H), 2.05 (dt, *J* = 13.6, 6.8 Hz, 1H), 1.95 (p, *J* = 7.2 Hz, 2H), 1.72–1.60 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 168.32, 159.98, 150.71, 134.56, 132.69,



128.13, 127.59, 125.79, 124.00, 121.38, 120.88 (2C), 118.78, 110.47, 109.53, 77.47, 68.20, 56.16 (2C), 46.30 (2C), 44.71, 43.23, 28.90, 25.94, 24.89. ESI HRMS, found 541.2225 (C₂₆H₃₂N₆O₅S, [M + H]⁺ requires 541.2228).

4.1.6.3 *N*-(2-Methoxy-4-((4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazolin-2-yl)piperazin-1-yl)sulfonyl)phenyl)acetamide (**21**). 4-Acetamido-3-methoxybenzenesulfonyl chloride (**5a**) was treated with 2-(piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**17a**) and K₂CO₃ in anhydrous DMF to afford **21** as a white solid. Yield = 92%. ¹H NMR (400 MHz, chloroform-*d*) δ 8.77 (d, *J* = 2.4 Hz, 1H), 8.01 (s, 1H), 7.78 (s, 1H), 7.66 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.59 (ddd, *J* = 10.0, 6.8, 1.6 Hz, 1H), 7.54–7.48 (m, 1H), 7.16 (ddd, *J* = 9.6, 6.8, 1.2 Hz, 1H), 6.95 (d, *J* = 8.8 Hz, 1H), 5.03 (s, 2H), 4.39 (t, *J* = 5.2 Hz, 2H), 4.09 (t, *J* = 5.6 Hz, 2H), 3.99 (dd, *J* = 8.0, 4.4 Hz, 4H), 3.94 (s, 3H), 3.11 (d, *J* = 7.6 Hz, 4H), 2.20 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 168.40, 164.72, 162.57, 157.08, 154.33, 151.07, 143.6 (q, *J* = 39.89 Hz, 1C), 133.53, 128.12, 127.50, 126.79, 124.07, 123.90, 122.03, 118.85, 118.3 (q, *J* = 258.56 Hz, 1C) 111.30, 109.62, 56.17, 46.39, 46.10, 45.93, 43.30, 43.05, 36.52, 31.45, 24.84. ESI HRMS, found 632.2013 (C₂₇H₂₈F₃N₉O₄S, [M + H]⁺ requires 632.2010).

4.1.6.4 1-(3-((4-(3-(Trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazolin-2-yl)piperazin-1-yl)sulfonyl)phenyl)ethan-1-one (**22**). 3-Acetylbenzenesulfonyl chloride (**7**) was treated with 2-(piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**17a**) and K₂CO₃ in anhydrous DMF to afford **22** as an off-white solid. Yield = 82%. ¹H NMR (400 MHz, chloroform-*d*) δ 8.04 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.68–7.60 (m, 2H), 7.55 (ddd, *J* = 13.2, 7.6, 1.2 Hz, 2H), 7.49 (dd, *J* = 8.8, 1.6 Hz, 1H), 7.32 (dd, *J* = 7.2, 1.2 Hz, 1H), 7.11 (ddd, *J* = 10.0, 6.8, 1.6 Hz, 1H), 5.03–4.91 (m, 2H), 4.31 (t, *J* = 5.6 Hz, 2H), 4.06–3.98 (m, 4H), 3.97–3.79 (m, 4H), 3.71–3.59 (m, 2H), 3.20 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 168.25, 164.78, 157.52, 151.14, 146.37, 143.6 (q, *J* = 40.20 Hz, 1C), 137.85, 136.68, 133.94, 133.57, 129.83, 129.74, 127.32, 126.87, 123.89, 122.09, 118.42 (q, *J* = 258.76 Hz, 1C), 111.43, 47.36, 46.84, 46.23, 45.56, 43.51, 43.40, 43.09, 41.90. ESI HRMS, found 587.1798 (C₂₆H₂₅F₃N₈O₃S, [M + H]⁺ requires 587.1795).

4.1.6.5 2-(4-((4-Nitrophenyl)sulfonyl)piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**23**). 4-Nitrobenzenesulfonyl chloride was treated with 2-(piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**14a**) and K₂CO₃ in anhydrous DMF to afford **23** as a white solid. Yield = 95%. ¹H NMR (400 MHz, chloroform-*d*) δ 8.38–8.33 (m, 2H), 8.02 (s, 1H), 7.97–7.92 (m, 2H), 7.56–7.48 (m, 1H), 7.42 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.09 (ddd, *J* = 9.2, 6.8, 1.2 Hz, 1H), 6.17 (t, *J* = 5.6 Hz, 1H), 4.07–4.00 (m, 4H), 3.92 (dt, *J* = 8.4, 6.8 Hz, 1H), 3.85–3.77 (m, 1H), 3.49 (ddd, *J* = 13.6, 7.6, 4.8 Hz, 1H), 3.13 (t, *J* = 5.2 Hz, 4H), 2.97 (s, 1H), 2.89 (d, *J* = 0.8 Hz, 1H), 2.07 (s, 1H), 1.94 (p, *J* = 6.4 Hz, 2H), 1.64 (dq, *J* = 20.0, 7.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 162.79, 160.13, 157.93, 151.25, 150.22, 141.69, 132.88, 128.93, 125.51, 124.37, 121.80, 121.04, 110.58, 68.21, 63.72, 46.03, 44.68, 43.34, 36.61, 31.53, 28.91, 25.88, 20.97. ESI HRMS, found 499.1756 (C₂₃H₂₆N₆O₅S, [M + H]⁺ requires 499.1758).

4.1.6.6 2-(4-((2-Nitrophenyl)sulfonyl)piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**24**). 3-Nitrobenzenesulfonyl chloride was treated with 2-(piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**14a**) and K₂CO₃ in anhydrous DMF to afford **24** as a white solid. Yield = 97%. ¹H NMR (400 MHz, chloroform-*d*) δ 8.01–7.94 (m, 1H), 7.73–7.64 (m, 2H), 7.62–7.56 (m, 1H), 7.53 (ddd, *J* = 9.2, 3.6, 2.4 Hz, 2H), 7.44 (d, *J* = 7.6 Hz, 1H), 7.14–7.06 (m, 1H), 6.09 (t, *J* = 5.2 Hz, 1H), 4.17 (qd, *J* = 7.2, 3.6 Hz, 1H), 4.04–3.99 (m, 4H), 3.93 (dt, *J* = 8.4, 6.8 Hz, 1H), 3.89–3.78 (m, 2H), 3.51 (ddd, *J* = 13.6, 7.6, 4.8 Hz, 1H), 3.37 (t, *J* = 5.2 Hz, 4H), 2.08 (s, 1H), 1.95 (p, *J* = 6.4 Hz, 2H), 1.71–1.62 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 160.12, 158.28, 151.59, 148.56, 133.78, 132.80, 131.49, 130.98, 130.88, 125.70, 124.07, 121.64, 120.99, 110.62, 77.55, 68.23, 63.70, 46.06, 44.69, 43.68, 28.91, 25.92, 20.88. ESI HRMS, found 499.1759 (C₂₃H₂₆N₆O₅S, [M + H]⁺ requires 499.1758).

4.1.6.7 2-(4-(Naphthalen-2-yl)sulfonyl)piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**25**). Naphthalene-2-sulfonyl chloride was treated with 2-(piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**14a**) and K₂CO₃ in anhydrous DMF to afford **25** as a yellow solid. Yield = 97%. ¹H NMR (400 MHz, chloroform-*d*) δ 8.27 (d, *J* = 1.6 Hz, 1H), 7.90–7.84 (m, 2H), 7.83–7.78 (m, 1H), 7.68 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.58–7.49 (m, 2H), 7.40 (dtd, *J* = 7.2, 3.6, 1.2 Hz, 2H), 7.31 (dd, *J* = 8.8, 1.2 Hz, 1H), 6.97 (ddd, *J* = 9.6, 6.8, 1.2 Hz, 1H), 5.88 (t, *J* = 5.6 Hz, 1H), 4.04 (qd, *J* = 7.2, 3.6 Hz, 1H), 3.94 (dd, *J* = 6.0, 4.0 Hz, 4H), 3.83 (dt, *J* = 8.4, 6.8 Hz, 1H), 3.76–3.67 (m, 2H), 3.39 (ddd, *J* = 13.6, 7.6, 4.8 Hz, 1H), 3.07 (t, *J* = 4.8 Hz, 4H), 2.00–1.90 (m, 1H), 1.84 (p, *J* = 6.4 Hz, 2H), 1.60–1.50 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 160.12, 158.25, 151.82, 135.00, 132.77, 132.67, 132.28, 129.33, 129.29, 129.23, 128.96, 128.01, 127.68, 125.84, 123.10, 121.52, 120.97, 110.60, 68.27, 46.35, 44.67, 43.34, 36.63, 31.54, 28.95, 25.98, 20.91. ESI HRMS, found 504.2068 (C₂₇H₂₉N₅O₃S, [M + H]⁺ requires 504.2064).

4.1.6.8 2-(4-((4-Nitrophenyl)sulfonyl)piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**26**). 4-Nitrobenzenesulfonyl chloride was treated with 2-(piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**17a**) and K₂CO₃ in anhydrous DMF to afford **26** as white solid. Yield = 95%. ¹H NMR (400 MHz, chloroform-*d*) δ 8.31–8.25 (m, 2H), 7.90–7.85 (m, 2H), 7.60 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.53 (ddd, *J* = 9.6, 6.4, 1.2 Hz, 1H), 7.45 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.11 (ddd, *J* = 9.6, 6.8, 1.2 Hz, 1H), 4.92 (s, 1H), 4.27 (t, *J* = 5.6 Hz, 2H), 4.02 (t, *J* = 5.6 Hz, 2H), 3.94 (dd, *J* = 6.0, 4.4 Hz, 4H), 3.67 (s, 1H), 3.05 (t, *J* = 5.2 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 164.84, 162.61, 156.94, 154.22, 151.16, 150.27, 146.19, 143.6 (q, *J* = 35.75 Hz, 1C), 141.58, 133.72, 128.93, 126.85, 124.42, 123.86, 122.39, 118.34 (q, *J* = 266.64 Hz, 1C), 111.46, 63.73, 47.10, 46.02, 45.91, 43.31, 43.11, 36.54. ESI HRMS, found 590.1545 (C₂₄H₂₂F₃N₉O₄S, [M + H]⁺ requires 590.1541).

4.1.6.9 2-(4-((2-Nitrophenyl)sulfonyl)piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**27**). 3-Nitrobenzenesulfonyl chloride was treated with 2-(piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**17a**) and K₂CO₃ in



anhydrous DMF to afford **27** as a white solid. Yield = 97%. ^1H NMR (400 MHz, chloroform-*d*) δ 8.03–7.96 (m, 1H), 7.75–7.66 (m, 3H), 7.65–7.58 (m, 2H), 7.56 (dd, $J = 8.8, 1.6$ Hz, 1H), 7.19 (ddd, $J = 10.0, 6.8, 1.6$ Hz, 1H), 5.05 (s, 2H), 4.39 (t, $J = 5.6$ Hz, 2H), 4.12 (t, $J = 5.2$ Hz, 2H), 4.00 (t, $J = 5.2$ Hz, 4H), 3.37 (t, $J = 5.2$ Hz, 4H). ^{13}C NMR (101 MHz, CDCl_3) δ 164.83, 157.17, 154.32, 151.11, 148.48, 143.6 (q, $J = 36.68$ Hz, 1C), 133.91, 133.65, 131.60, 131.04, 130.88, 126.87, 124.14, 123.92, 122.27, 118.3 (q, $J = 248.86$ Hz, 1C), 111.45, 46.77, 46.26, 45.86 (2C), 43.71 (2C), 43.08. ESI HRMS, found 590.1542 ($\text{C}_{24}\text{H}_{22}\text{F}_3\text{N}_9\text{O}_4\text{S}$, $[\text{M} + \text{H}]^+$ requires 590.1541).

4.1.6.10 2-(4-(Naphthalen-2-ylsulfonyl)piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**28**). Naphthalene-2-sulfonyl chloride was treated with 2-(piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**17a**) and K_2CO_3 in anhydrous DMF to afford **28** as a yellow solid. Yield = 97%. ^1H NMR (400 MHz, chloroform-*d*) δ 8.34 (d, $J = 2.0$ Hz, 1H), 7.96 (t, $J = 7.6$ Hz, 2H), 7.91–7.86 (m, 1H), 7.75 (dd, $J = 8.8, 2.0$ Hz, 1H), 7.62 (dtd, $J = 8.8, 4.4, 1.6$ Hz, 3H), 7.57 (ddd, $J = 6.8, 2.4, 1.6$ Hz, 1H), 7.49 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.14 (ddd, $J = 9.6, 6.8, 1.2$ Hz, 1H), 4.98 (s, 2H), 4.34 (t, $J = 5.6$ Hz, 2H), 4.05 (t, $J = 5.2$ Hz, 2H), 4.00 (dd, $J = 6.0, 4.4$ Hz, 4H), 3.13 (t, $J = 5.2$ Hz, 4H). ^{13}C NMR (101 MHz, CDCl_3) δ 164.75, 157.00, 154.30, 151.12, 143.6 (q, $J = 36.16$ Hz, 1C), 134.93, 133.57, 132.80, 132.44, 132.19, 129.32, 129.26, 129.16, 128.96, 127.91, 127.67, 126.79, 123.83, 122.97, 122.12, 118.4 (q, $J = 256.64$ Hz, 1C), 111.36, 46.90, 46.10 (2C), 43.33 (2C), 43.11. ESI HRMS, found 595.1845 ($\text{C}_{28}\text{H}_{25}\text{F}_3\text{N}_8\text{O}_2\text{S}$, $[\text{M} + \text{H}]^+$ requires 595.1846).

4.1.6.11 4-((4-(4-((Tetrahydrofuran-2-yl)methyl)amino)quinazolin-2-yl)piperazin-1-yl)sulfonyl)benzotrile (**29**). 4-Cyanobenzenesulfonyl chloride was treated with 2-(piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**14a**) and K_2CO_3 in anhydrous DMF to afford **29** as an off-white solid. Yield = 98%. ^1H NMR (400 MHz, chloroform-*d*) δ 7.82–7.72 (m, 4H), 7.44 (dd, $J = 6.8, 1.2$ Hz, 2H), 7.33 (dd, $J = 9.2, 1.2$ Hz, 1H), 7.02 (td, $J = 14.8, 6.8, 1.2$ Hz, 1H), 5.86 (t, $J = 5.2$ Hz, 1H), 4.06 (qd, $J = 7.2, 3.6$ Hz, 1H), 3.95 (dd, $J = 6.4, 4.4$ Hz, 4H), 3.85 (dt, $J = 8.4, 6.4$ Hz, 1H), 3.74 (tt, $J = 13.6, 6.4, 3.6$ Hz, 2H), 3.40 (ddd, $J = 13.6, 7.6, 4.8$ Hz, 1H), 3.03 (t, $J = 5.2$ Hz, 4H), 2.00–1.91 (m, 1H), 1.87 (p, $J = 7.2$ Hz, 2H), 1.62–1.52 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 160.11, 158.19, 151.84, 140.20, 132.90 (2C), 132.77, 128.33 (2C), 125.96, 121.62, 120.87, 117.20, 116.65, 110.60, 77.37, 68.22, 46.07 (2C), 44.68, 43.23 (2C), 28.92, 25.93. ESI HRMS, found 479.1862 ($\text{C}_{24}\text{H}_{26}\text{N}_6\text{O}_3\text{S}$, $[\text{M} + \text{H}]^+$ requires 479.1860).

4.1.6.12 4-((4-(3-(Trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazolin-2-yl)piperazin-1-yl)sulfonyl)benzotrile (**30**). 4-Cyanobenzenesulfonyl chloride was treated with 2-(piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**17a**) and K_2CO_3 in anhydrous DMF to afford **30** as a white solid. Yield = 98%. ^1H NMR (400 MHz, chloroform-*d*) δ 7.90–7.81 (m, 4H), 7.68 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.61 (ddd, $J = 10.0, 6.8, 1.2$ Hz, 1H), 7.53 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.19 (ddd, $J = 9.6, 6.8, 1.2$ Hz, 1H), 5.00 (s, 2H), 4.35 (t, $J = 5.2$ Hz, 2H), 4.09 (t, $J = 5.6$ Hz, 2H), 4.01 (t, $J = 5.2$ Hz, 4H), 3.10 (t, $J = 5.2$ Hz, 4H). ^{13}C NMR (101 MHz,

CDCl_3) δ 164.85, 156.96, 154.25, 151.16, 143.6 (q, $J = 39.29$ Hz, 1C), 140.03, 133.72, 132.97 (2C), 128.33 (2C), 126.86, 123.86, 122.38, 118.4 (q, $J = 271.89$ Hz, 1C), 117.15, 116.76, 111.47, 47.12, 46.03, 45.91 (2C), 43.30 (2C), 43.10. ESI HRMS, found 570.1646 ($\text{C}_{25}\text{H}_{22}\text{F}_3\text{N}_9\text{O}_2\text{S}$, $[\text{M} + \text{H}]^+$ requires 570.1642).

4.1.6.13 2-(4-(Pyridin-3-ylsulfonyl)piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**31**). Pyridine-3-sulfonyl chloride was treated with 2-(piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**14a**) and K_2CO_3 in anhydrous DMF to afford **31** as an off-white solid. Yield = 95%. ^1H NMR (400 MHz, chloroform-*d*) δ 8.93 (dd, $J = 2.0, 0.8$ Hz, 1H), 8.73 (dd, $J = 5.2, 1.6$ Hz, 1H), 7.98 (ddd, $J = 8.0, 2.4, 1.6$ Hz, 1H), 7.48–7.42 (m, 2H), 7.42–7.33 (m, 2H), 7.06–6.98 (m, 1H), 5.95 (s, 1H), 4.07 (qd, $J = 7.2, 3.6$ Hz, 1H), 3.97 (t, $J = 5.2$ Hz, 4H), 3.85 (dt, $J = 8.4, 6.8$ Hz, 1H), 3.80–3.70 (m, 2H), 3.41 (ddd, $J = 13.6, 7.6, 4.8$ Hz, 1H), 3.06 (t, $J = 4.8$ Hz, 4H), 2.02–1.92 (m, 1H), 1.87 (p, $J = 6.4$ Hz, 2H), 1.63–1.54 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 162.62, 160.11, 153.46, 148.51, 135.45, 132.80, 132.51, 125.85, 123.78 (2C), 121.67, 120.92, 110.58, 68.21, 63.72, 46.03, 44.69, 43.28, 36.52, 31.47, 28.92, 25.91. ESI HRMS, found 455.1856 ($\text{C}_{22}\text{H}_{26}\text{N}_6\text{O}_3\text{S}$, $[\text{M} + \text{H}]^+$ requires 455.1860).

4.1.6.14 *N*-((Tetrahydrofuran-2-yl)methyl)-2-(4-(thiophen-2-ylsulfonyl)piperazin-1-yl)quinazolin-4-amine (**32**). Thiophene-2-sulfonyl chloride was treated with 2-(piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**14a**) and K_2CO_3 in anhydrous DMF to afford **32** as a white solid. Yield = 94%. ^1H NMR (400 MHz, chloroform-*d*) δ 7.59 (dd, $J = 4.8, 1.2$ Hz, 1H), 7.54 (dd, $J = 3.6, 1.2$ Hz, 1H), 7.53–7.48 (m, 2H), 7.42 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.14–7.05 (m, 2H), 5.93 (s, 1H), 4.15 (qd, $J = 7.2, 3.6$ Hz, 1H), 4.04 (t, $J = 4.8$ Hz, 4H), 3.92 (dt, $J = 8.4, 6.8$ Hz, 1H), 3.88–3.77 (m, 2H), 3.49 (ddd, $J = 14.0, 7.6, 4.8$ Hz, 1H), 3.14 (t, $J = 4.8$ Hz, 4H), 2.04 (ddd, $J = 18.0, 12.0, 6.8$ Hz, 1H), 1.94 (p, $J = 6.8$ Hz, 2H), 1.70–1.60 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 160.10, 158.32, 151.93, 135.84, 132.72, 132.55, 132.22, 127.70, 125.96, 121.49, 120.86, 110.59, 68.22, 46.22 (2C), 44.67, 43.11 (2C), 30.95, 28.91, 25.94. ESI HRMS, found 460.1474 ($\text{C}_{21}\text{H}_{25}\text{N}_5\text{O}_3\text{S}_2$, $[\text{M} + \text{H}]^+$ requires 460.1472).

4.1.6.15 2-(4-((5-Chlorothiophen-2-yl)sulfonyl)piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**33**). 5-Chlorothiophene-2-sulfonyl chloride was treated with 2-(piperazin-1-yl)-*N*-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine (**14a**) and K_2CO_3 in anhydrous DMF to afford **33** as a white solid. Yield = 96%. ^1H NMR (400 MHz, chloroform-*d*) δ 7.57–7.48 (m, 2H), 7.43 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.31 (d, $J = 4.0$ Hz, 1H), 7.13–7.05 (m, 1H), 6.95 (d, $J = 4.0$ Hz, 1H), 5.95 (t, $J = 5.2$ Hz, 1H), 4.15 (qt, $J = 7.2, 3.6$ Hz, 1H), 4.05 (dd, $J = 6.0, 4.4$ Hz, 4H), 3.93 (dt, $J = 8.0, 6.8$ Hz, 1H), 3.89–3.76 (m, 2H), 3.50 (ddd, $J = 13.6, 7.6, 4.8$ Hz, 1H), 3.14 (t, $J = 5.2$ Hz, 4H), 2.09–2.00 (m, 1H), 1.95 (p, $J = 6.4$ Hz, 2H), 1.71–1.61 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 160.13, 158.25, 151.89, 137.57, 133.84, 132.76, 131.92, 127.16 (2C), 125.95, 121.56, 120.90, 110.61, 68.23, 46.16 (2C), 44.68, 43.08 (2C), 28.92, 25.94. ESI HRMS, found 494.1082 ($\text{C}_{21}\text{H}_{24}\text{ClN}_5\text{O}_3\text{S}_2$, $[\text{M} + \text{H}]^+$ requires 494.1082).

4.1.6.16 2-(4-((5-Chlorothiophen-2-yl)sulfonyl)piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**34**). 5-Chlorothiophene-2-sulfonyl chloride



was treated with 2-(piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**17a**) and K_2CO_3 in anhydrous DMF to afford **34** as a white solid. Yield = 97%. 1H NMR (400 MHz, chloroform-*d*) δ 7.69 (dd, $J = 8.0$, 1.2 Hz, 1H), 7.62 (ddd, $J = 10.0$, 6.8, 1.6 Hz, 1H), 7.55 (dd, $J = 8.4$, 1.2 Hz, 1H), 7.33 (d, $J = 4.0$ Hz, 1H), 7.19 (ddd, $J = 9.6$, 6.8, 1.2 Hz, 1H), 6.96 (d, $J = 4.0$ Hz, 1H), 5.03 (s, 2H), 4.38 (t, $J = 5.6$ Hz, 2H), 4.11 (t, $J = 5.6$ Hz, 2H), 4.04 (dd, $J = 6.0$, 4.0 Hz, 4H), 3.14 (t, $J = 5.2$ Hz, 4H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 164.86, 157.04, 154.33, 151.12, 143.6 (q, $J = 39.89$ Hz, 1C), 137.74, 133.74, 133.67, 132.05, 127.20, 126.89, 123.88, 122.28, 118.34 (q, $J = 251.79$ Hz, 1C), 111.47, 46.94, 46.19, 45.98 (2C), 43.18 (2C), 43.12. ESI HRMS, found 585.0865 ($C_{22}H_{20}ClF_3N_8O_2S_2$, $[M + H]^+$ requires 585.0864).

4.1.6.17 2-(4-(Pyridin-3-ylsulfonyl)piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**35**). Pyridine-3-sulfonyl chloride was treated with 2-(piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**17a**) and K_2CO_3 in anhydrous DMF to afford **35** as an off-white solid. Yield = 94%. 1H NMR (400 MHz, chloroform-*d*) δ 8.92 (dd, $J = 2.4$, 0.8 Hz, 1H), 8.74 (dd, $J = 4.8$, 1.6 Hz, 1H), 8.03–7.97 (m, 1H), 7.60 (dd, $J = 8.0$, 1.2 Hz, 1H), 7.54 (ddd, $J = 10.0$, 6.8, 1.2 Hz, 1H), 7.47 (dd, $J = 8.4$, 1.2 Hz, 1H), 7.42 (ddd, $J = 8.0$, 4.8, 0.8 Hz, 1H), 7.11 (ddd, $J = 9.6$, 6.8, 1.6 Hz, 1H), 4.94 (s, 2H), 4.30 (t, $J = 5.6$ Hz, 2H), 4.02 (t, $J = 5.2$ Hz, 2H), 3.95 (dd, $J = 6.0$, 4.4 Hz, 4H), 3.06 (t, $J = 5.2$ Hz, 4H). ^{13}C NMR (101 MHz, DMSO) δ 164.87, 157.09, 154.21, 153.72, 152.14, 147.98, 143.1 (q, $J = 31.81$ Hz, 1C), 136.27, 133.94, 132.00, 126.07, 125.33, 125.10, 122.40, 118.7 (q, $J = 274.21$ Hz, 1C), 111.53, 63.02, 46.72, 45.98 (2C), 45.51, 43.26 (2C). ESI HRMS, found 546.1644 ($C_{23}H_{22}F_3N_9O_2S_2$, $[M + H]^+$ requires 546.1642).

4.1.6.18 2-(4-(Thiophen-2-ylsulfonyl)piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**36**). Thiophene-2-sulfonyl chloride was treated with 2-(piperazin-1-yl)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl)quinazoline (**17a**) and K_2CO_3 in anhydrous DMF to afford **36** as a white solid. Yield = 96%. 1H NMR (400 MHz, chloroform-*d*) δ 7.68 (dd, $J = 8.0$, 1.2 Hz, 1H), 7.63–7.59 (m, 2H), 7.56–7.53 (m, 2H), 7.18 (ddd, $J = 9.6$, 6.8, 1.2 Hz, 1H), 7.13 (dd, $J = 5.2$, 4.0 Hz, 1H), 5.03 (s, 2H), 4.38 (t, $J = 5.2$ Hz, 2H), 4.10 (t, $J = 5.6$ Hz, 2H), 4.03 (dd, $J = 6.0$, 4.0 Hz, 4H), 3.13 (t, $J = 5.2$ Hz, 4H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 164.82, 157.09, 154.32, 151.12, 143.6 (q, $J = 38.88$ Hz, 1C), 135.64, 133.65, 132.69, 132.40, 127.79, 126.84, 123.89, 122.23, 118.3 (q, $J = 246.64$ Hz, 1C), 111.42, 46.89, 46.19, 46.04 (2C), 43.20 (2C), 43.12. ESI HRMS, found 551.1250 ($C_{22}H_{21}F_3N_8O_2S_2$, $[M + H]^+$ requires 551.1254).

4.2. *P. falciparum* culture and inhibition assay

The *P. falciparum* 3D7 strain of malaria parasite was cultured following a well-described protocol, as previously outlined.⁶⁴ Human erythrocytes (4% hematocrit) were supplemented with 0.5% albumax and 4% hematocrit in RPMI media, and they were synchronised by frequent sorbitol treatment. The growth inhibition assay was performed in triplicate and repeated twice.

The desired concentration (0–100 μM) was achieved by adding 4 μL of the test compound to each well of the 96-well plate. Parasite culture (96 μL) at 1% parasitemia (3 to 10 h p.i.) and 2% hematocrit was added to each well of the 96-well plate and was incubated for the next 48 h. As a control experiment, along with test compounds, 4 μM chloroquine and 0.4% DMSO were used. As described by Smilkstein, *et al.*,⁶⁵ a DNA fluorescent dye-binding assay using SYBR green was carried out after incubation for 48 h to assess the parasite's development in each well.

4.3. Cytotoxicity assay

The associated cytotoxicity was investigated against the cancerous cell line A549 by employing the reported protocol⁶⁶ and THP1 monocytes. The MTT assay was used to measure the cell viability, which is mostly reliant on the mitochondrial activity of the cell. It is based on the reduction of a tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] to a formazan. Dulbecco's modified Eagle's medium, augmented with 10% fetal bovine serum, was used to grow the A549 cells. The cells at a density of 1×10^4 cells per well in a 160 μL medium were incubated at 37 $^\circ C$ for 24 h in a 96-well plate to seed, followed by the addition of the test compounds in different concentrations. The media was discarded after incubation for 24 h, followed by the addition of 25 μL of 4 mmgg mL⁻¹ of MTT, and further incubated for 4 h. After discarding the media, the formazan crystals were liquified by the addition of 200 μL of DMSO. To calculate the IC_{50} values, each experiment was independently performed in triplicate, and the cell viability was obtained by comparing control wells. The IC_{50} values were calculated using the nonlinear regression analysis method of GraphPad Prism, US.

Moreover, THP1 monocytes were maintained in RPMI-1640 medium. Cells were cultured at 37 $^\circ C$ in a 5% CO_2 environment. All media were supplemented with 10% fetal bovine serum (FBS). The cells were stimulated by administering Phorbol 12-Myristate 13-Acetate (PMA). The activated macrophages were seeded into a 96-well microtiter plate (2×10^4 cells per well) in five replicates for each condition and treated with compounds at concentrations of 100 μM and 500 μM . After 24 h, 100 μL of MTT stock solution (1 mg mL⁻¹) was added to each well. The cells were then incubated at 37 $^\circ C$ for 45 minutes. The coloured formazan crystals were dissolved in 100 μL of DMSO. The OD values of the solutions were measured at 595 nm using a plate reader.

4.4. *In silico* studies

4.4.1. Docking studies. Molecular docking was performed to explore the possible biological target of the synthesised molecular hybrids. The crystallographic structure of food vacuole targets of *P. falciparum*, *i.e.* plasmepsins I, II, IV, and X, were retrieved from the RCSB Protein Data Bank (<http://www.rcsb.org>) associated with PDB IDs 3QS1, 1SME, 5I7O, and 7TBC, respectively. Similarly, the crystal structures FP2, FP3, FLN, and HAP were downloaded, associated with PDB IDs 3BPF, 3BWK, 7DIJ, and 3QVI, respectively. The crystal structures of plasmepsin IX and HDP were not available in



the RCSB PDB database; hence, v4 model structures with UniProt IDs Q8ILG2 and Q8IL04, respectively, were downloaded from the AlphaFold database for docking studies. The ligands were drawn in the 2D sketcher tool, minimised using workspace operations, and prepared using the LigPrep module of the Schrödinger suite. The target proteins were prepared using the protein preparation wizard by filling missing side chains and loops using the Prime module. The receptor grid was generated using the receptor grid generation in the Glide application by specifying the bound ligand, which was identified by the SiteMap tool.⁶⁷ The designed ligands were subjected to molecular docking using the Glide module of the Schrödinger suite.⁶⁸ For each ligand, the pose exhibiting the lowest docking score was retained as the optimal binding conformation. The orientation corresponding to the most favourable binding free energy (*i.e.*, strongest predicted affinity) was selected for subsequent structural characterisation of the protein–ligand complex. This analysis, performed in Maestro within the Schrödinger environment,⁶⁸ includes evaluation of hydrogen bonding patterns, hydrophobic contacts, and bond geometries such as bond lengths and angles.

4.4.2. MD simulation and MM-GBSA studies. Selected protein–ligand complexes obtained from docking studies were subjected to MD simulation using the Desmond module of the Schrödinger environment. The complexes were prepared using the System Builder of the Desmond using the SPC water model, orthorhombic box shape, and OPLS4 force field. The systems were neutralised by adding Na⁺ ions, followed by the addition of 0.15 M NaCl salt. The prepared complexes were subjected to a 200 ns MD simulation at NPT, and the trajectory was recorded at every 100 ps interval. The temperature was kept at 310 K under 1.01 bar pressure, and the model system was relaxed before simulation using the option of Maestro GUI. The ‘Simulation Interaction Diagram’ module in the Desmond wizard of Schrödinger Maestro was used to post-process and analyse the trajectories of the MD simulations.

To calculate the binding free energy, the MM-GBSA calculations were carried out post-MD simulations using ‘thermal_mmgbsa.py’, a Python script of the Schrödinger.⁶⁹ This script calculates the binding free energies of the ligand–protein complexes, an essential aspect of understanding the interaction dynamics. The general structure of the command used for running the script was “run thermal_mmgbsa.py -j [name_of_job] -o [output_file_name.csv] -step_size [step] -HOST [host_name] -NJOBS 10 -lig_asl [ligand_name] [input_cms_file]”. In this study, the script was executed with a step size of 10 to analyse each frame from 0 to 200 ns.

4.4.3. ADME prediction and drug-likeness. The QikProp module of the Schrödinger suite was used to predict pharmacokinetic parameters, including absorption, distribution, metabolism, and excretion, of the compounds. The energy of the ligands was minimised using the Workspace Ligand Minimisation tool, followed by geometry optimisation employing the MOPAC2016 module, with the PM7 method. The optimised ligands were subjected to the QikProp job in the normal mode with default parameters, and the results were recorded.

Author contributions

HM: design, methodology, chemical synthesis, characterisation, rigorous computational studies, evaluation of the results, and writing the original draft of the manuscript. AP: designing and performing antimalarial assays, compiling and analysing the antimalarial activity results. AR and SB: designing and performing cytotoxicity assays on A549 cells. KS: synthesis of intermediates. DD and DK: design and supervision of cytotoxicity assays of THP1 cells, analysis of the results, and reviewing and editing the original draft. ATK: reviewing the original draft. PM: design and supervision of antimalarial assays, analysis of the results, and reviewing and editing the original draft. NH: conceptualisation, methodology, study supervision, resources, investigation of the results, reviewing and editing the original draft, and arrangement of funds.

Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

The data supporting this article have been included as part of the supplementary information (SI). Supplementary information is available. See DOI: <https://doi.org/10.1039/d5ra08515b>.

Acknowledgements

The author HM would like to acknowledge the Department of Biotechnology and Indian Council of Medical Research, Government of India, New Delhi, India, for providing financial support during the study as the M K Bhan-Young Researcher Fellowship Program (File No. HRD-16016/17/2025-HRD-DBT) and a Senior Research Fellowship (Award No. 45/02/2020-Nan/BMS), respectively. The PM acknowledges the DBT-Wellcome Team Science Grant (WTA/24/006) and the JC Bose Grant (DST/20/015) for providing financial support during the study. The NH acknowledges the Indian Council for Medical Research (ICMR), New Delhi, India (BMI/Adhoc/36/2022–23) for providing financial support during the study. We also thank the Rotary Blood Bank, New Delhi, India, for providing human red blood cells.

References

- 1 World Health Organisation, *World Malaria Report 2024: Addressing Inequity in the Global Malaria Response*, Geneva, 2024.
- 2 B. Hanboonkunupakarn and N. J. White, Advances and roadblocks in the treatment of malaria, *Br. J. Clin. Pharmacol.*, 2022, **88**, 374–382, DOI: [10.1111/bcp.14474](https://doi.org/10.1111/bcp.14474).
- 3 H. Madhav and N. Hoda, An insight into the recent development of the clinical candidates for the treatment of



- malaria and their target proteins, *Eur. J. Med. Chem.*, 2021, **210**, 112955, DOI: [10.1016/j.ejmech.2020.112955](https://doi.org/10.1016/j.ejmech.2020.112955).
- 4 P. Jagannathan and A. Kakuru, Malaria in 2022: Increasing challenges, cautious optimism, *Nat. Commun.*, 2022, **13**, 2678, DOI: [10.1038/s41467-022-30133-w](https://doi.org/10.1038/s41467-022-30133-w).
- 5 R. W. van der Pluijm, R. Tripura, R. M. Hoglund, A. Pyae Phyo, D. Lek, A. ul Islam, A. R. Anvikar, P. Satpathi, S. Satpathi, P. K. Behera, A. Tripura, S. Baidya, M. Onyamboko, N. H. Chau, Y. Sovann, S. Suon, S. Sreng, S. Mao, S. Oun, S. Yen, C. Amaratunga, K. Chutasmit, C. Saelow, R. Runcharern, W. Kaewmok, N. T. Hoa, N. V. Thanh, B. Hanboonkunupakarn, J. J. Callery, A. K. Mohanty, J. Heaton, M. Thant, K. Gantait, T. Ghosh, R. Amato, R. D. Pearson, C. G. Jacob, S. Gonçalves, M. Mukaka, N. Waithira, C. J. Woodrow, M. P. Grobusch, M. van Vugt, R. M. Fairhurst, P. Y. Cheah, T. J. Peto, L. von Seidlein, M. Dhorda, R. J. Maude, M. Winterberg, N. T. Thuy-Nhien, D. P. Kwiatkowski, M. Imwong, P. Jittamala, K. Lin, T. M. Hlaing, K. Chotivanich, R. Huy, C. Fanello, E. Ashley, M. Mayxay, P. N. Newton, T. T. Hien, N. Valecha, F. Smithuis, S. Pukrittayakamee, A. Faiz, O. Miotto, J. Tarning, N. P. J. Day, N. J. White, A. M. Dondorp, R. W. van der Pluijm, R. Tripura, R. M. Hoglund, A. P. Phyo, D. Lek, A. ul Islam, A. R. Anvikar, P. Satpathi, S. Satpathi, P. K. Behera, A. Tripura, S. Baidya, M. Onyamboko, N. H. Chau, Y. Sovann, S. Suon, S. Sreng, S. Mao, S. Oun, S. Yen, C. Amaratunga, K. Chutasmit, C. Saelow, R. Runcharern, W. Kaewmok, N. T. Hoa, N. V. Thanh, B. Hanboonkunupakarn, J. J. Callery, A. K. Mohanty, J. Heaton, M. Thant, K. Gantait, T. Ghosh, R. Amato, R. D. Pearson, C. G. Jacob, S. Gonçalves, M. Mukaka, N. Waithira, C. J. Woodrow, M. P. Grobusch, M. van Vugt, R. M. Fairhurst, P. Y. Cheah, T. J. Peto, L. von Seidlein, M. Dhorda, R. J. Maude, M. Winterberg, N. T. Thuy-Nhien, D. P. Kwiatkowski, M. Imwong, P. Jittamala, K. Lin, T. M. Hlaing, K. Chotivanich, R. Huy, C. Fanello, E. Ashley, M. Mayxay, P. N. Newton, T. T. Hien, N. Valeche, F. Smithuis, S. Pukrittayakamee, A. Faiz, O. Miotto, J. Tarning, N. P. Day, N. J. White and A. M. Dondorp, Triple artemisinin-based combination therapies *versus* artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial, *Lancet*, 2020, **395**, 1345–1360, DOI: [10.1016/S0140-6736\(20\)30552-3](https://doi.org/10.1016/S0140-6736(20)30552-3).
- 6 T. J. Peto, R. Tripura, J. J. Callery, D. Lek, H. D. T. Nghia, C. Nguon, N. T. H. Thuong, R. W. van der Pluijm, N. T. P. Dung, M. Sokha, V. Van Luong, L. T. Long, Y. Sovann, J. Duanguppama, N. Waithira, R. M. Hoglund, P. Chotsiri, N. H. Chau, A. Ruecker, C. Amaratunga, M. Dhorda, O. Miotto, R. J. Maude, H. Rekol, K. Chotivanich, J. Tarning, L. von Seidlein, M. Imwong, M. Mukaka, N. P. J. Day, T. T. Hien, N. J. White and A. M. Dondorp, Triple therapy with artemether-lumefantrine plus amodiaquine *versus* artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial, *Lancet Infect. Dis.*, 2022, **22**, 867–878, DOI: [10.1016/S1473-3099\(21\)00692-7](https://doi.org/10.1016/S1473-3099(21)00692-7).
- 7 T. D. Ashton, A. Ngo, P. Favuzza, H. E. Bullen, M. R. Gancheva, O. Romeo, M. Parkyn Schneider, N. Nguyen, R. W. J. Steel, S. Duffy, K. N. Lowes, H. J. Sabroux, V. M. Avery, J. A. Boddey, D. W. Wilson, A. F. Cowman, P. R. Gilson and B. E. Sleebs, Property activity refinement of 2-anilino 4-amino substituted quinazolines as antimalarials with fast acting asexual parasite activity, *Bioorg. Chem.*, 2021, **117**, 105359, DOI: [10.1016/j.bioorg.2021.105359](https://doi.org/10.1016/j.bioorg.2021.105359).
- 8 S. Malasala, M. N. Ahmad, R. Akunuri, M. Shukla, G. Kaul, A. Dasgupta, Y. V. Madhavi, S. Chopra and S. Nanduri, Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis, *Eur. J. Med. Chem.*, 2021, **212**, 112996, DOI: [10.1016/j.ejmech.2020.112996](https://doi.org/10.1016/j.ejmech.2020.112996).
- 9 S. S. Al Neyadi, A. G. Al Blooshi, H. L. Nguyen and M. A. Alnaqbi, UiO-66-NH₂ as an effective solid support for quinazoline derivatives for antibacterial agents against Gram-negative bacteria, *New J. Chem.*, 2021, **45**, 20386–20395, DOI: [10.1039/D1NJ03749H](https://doi.org/10.1039/D1NJ03749H).
- 10 S. Shagufta and I. Ahmad, An insight into the therapeutic potential of quinazoline derivatives as anticancer agents, *Medchemcomm*, 2017, **8**, 871–885, DOI: [10.1039/C7MD00097A](https://doi.org/10.1039/C7MD00097A).
- 11 Y. Mizukawa, M. Ikegami-Kawai, M. Horiuchi, M. Kaiser, M. Kojima, S. Sakanoue, S. Miyagi, C. Nanga Chick, H. Togashi, M. Tsubuki, M. Ihara, T. Usuki and I. Itoh, Quest for a potent antimalarial drug lead: Synthesis and evaluation of 6,7-dimethoxyquinazoline-2,4-diamines, *Bioorg. Med. Chem.*, 2021, **33**, 116018, DOI: [10.1016/j.bmc.2021.116018](https://doi.org/10.1016/j.bmc.2021.116018).
- 12 A. Dutta, P. Trivedi, P. S. Gehlot, D. Gogoi, R. Hazarika, P. Chetia, A. Kumar, A. K. Chaliha, V. Chaturvedi and D. Sarma, Design and Synthesis of Quinazolinone-Triazole Hybrids as Potent Anti-Tubercular Agents, *ACS Appl. Bio Mater.*, 2022, **5**(9), 4413–4424, DOI: [10.1021/acsabm.2c00562](https://doi.org/10.1021/acsabm.2c00562).
- 13 P. R. Gilson, C. Tan, K. E. Jarman, K. N. Lowes, J. M. Curtis, W. Nguyen, A. E. Di Rago, H. E. Bullen, B. Prinz, S. Duffy, J. B. Baell, C. A. Hutton, H. Jousset Subroux, B. S. Crabb, V. M. Avery, A. F. Cowman and B. E. Sleebs, Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral *in Vivo* Activity, *J. Med. Chem.*, 2017, **60**, 1171–1188, DOI: [10.1021/acs.jmedchem.6b01673](https://doi.org/10.1021/acs.jmedchem.6b01673).
- 14 A. Bouchut, D. Rotili, C. Pierrot, S. Valente, S. Lafitte, J. Schultz, U. Hoglund, R. Mazzone, A. Lucidi, G. Fabrizi, D. Pechalrieu, P. B. Arimondo, T. S. Skinner-Adams, M. J. Chua, K. T. Andrews, A. Mai and J. Khalife, Identification of novel quinazoline derivatives as potent antiplasmodial agents, *Eur. J. Med. Chem.*, 2019, **161**, 277–291, DOI: [10.1016/j.ejmech.2018.10.041](https://doi.org/10.1016/j.ejmech.2018.10.041).
- 15 T. Fröhlich, C. Reiter, M. M. Ibrahim, J. Beutel, C. Hutterer, I. Zeiträger, H. Bahsi, M. Leidenberger, O. Friedrich,



- B. Kappes, T. Efferth, M. Marschall and S. B. Tsogoeva, Synthesis of Novel Hybrids of Quinazoline and Artemisinin with High Activities against Plasmodium falciparum, Human Cytomegalovirus, and Leukemia Cells, *ACS Omega*, 2017, 2, 2422–2431, DOI: [10.1021/acsomega.7b00310](https://doi.org/10.1021/acsomega.7b00310).
- 16 A. H. Shntaif, S. Khan, G. Tapadiya, A. Chettupalli, S. Saboo, M. S. Shaikh, F. Siddiqui and R. R. Amara, Rational drug design, synthesis, and biological evaluation of novel N-(2-arylamino-phenyl)-2,3-diphenylquinoxaline-6-sulfonamides as potential antimalarial, antifungal, and antibacterial agents, *Digit. Chinese Med.*, 2021, 4, 290–304, DOI: [10.1016/j.dcm.2021.12.004](https://doi.org/10.1016/j.dcm.2021.12.004).
- 17 M. N. Peerzada, P. Khan, K. Ahmad, M. I. Hassan and A. Azam, Synthesis, characterization and biological evaluation of tertiary sulfonamide derivatives of pyridyl-indole based heteroaryl chalcone as potential carbonic anhydrase IX inhibitors and anticancer agents, *Eur. J. Med. Chem.*, 2018, 155, 13–23, DOI: [10.1016/j.ejmech.2018.05.034](https://doi.org/10.1016/j.ejmech.2018.05.034).
- 18 K. N. de Oliveira, P. Costa, J. R. Santin, L. Mazzambani, C. Bürger, C. Mora, R. J. Nunes and M. M. de Souza, Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonyl-hydrazones, *Bioorg. Med. Chem.*, 2011, 19, 4295–4306, DOI: [10.1016/j.bmc.2011.05.056](https://doi.org/10.1016/j.bmc.2011.05.056).
- 19 J. A. Ezugwu, U. C. Okoro, M. A. Ezeokonkwo, K. S. Hariprasad, M. Rudrapal, D. I. Ugwu, N. Gogoi, D. Chetia, I. Celik and O. C. Ekoh, Design, Synthesis, Molecular Docking, Molecular Dynamics and *In Vivo* Antimalarial Activity of New Dipeptide-Sulfonamides, *ChemistrySelect*, 2022, 7(5), e202103908, DOI: [10.1002/slct.202103908](https://doi.org/10.1002/slct.202103908).
- 20 A. Sabt, O. M. Abdelhafez, R. S. El-Haggar, H. M. F. Madkour, W. M. Eldehna, E. E.-D. A. El-Khrisy, M. A. Abdel-Rahman and L. A. Rashed, Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, *in vitro* biological evaluation, and QSAR studies, *J. Enzyme Inhib. Med. Chem.*, 2018, 33, 1095–1107, DOI: [10.1080/14756366.2018.1477137](https://doi.org/10.1080/14756366.2018.1477137).
- 21 M. V. Papadopoulou, W. D. Bloomer, H. S. Rosenzweig, A. Arena, F. Arrieta, J. C. J. Rebolledo and D. K. Smith, Nitrotriazole- and Imidazole-Based Amides and Sulfonamides as Antitubercular Agents, *Antimicrob. Agents Chemother.*, 2014, 58, 6828–6836, DOI: [10.1128/AAC.03644-14](https://doi.org/10.1128/AAC.03644-14).
- 22 R. Pingaew, P. Mandi, V. Prachayasittikul, A. Thongnum, S. Prachayasittikul, S. Ruchirawat and V. Prachayasittikul, Investigations on Anticancer and Antimalarial Activities of Indole-Sulfonamide Derivatives and *In Silico* Studies, *ACS Omega*, 2021, 6, 31854–31868, DOI: [10.1021/acsomega.1c04552](https://doi.org/10.1021/acsomega.1c04552).
- 23 V. R. Karpina, S. S. Kovalenko, S. M. Kovalenko, O. G. Drushlyak, N. D. Bunyatyan, V. A. Georgiyants, V. V. Ivanov, T. Langer and L. Maes, A Novel Series of [1,2,4]Triazololo[4,3-a]Pyridine Sulfonamides as Potential Antimalarial Agents: *In Silico* Studies, Synthesis and *In Vitro* Evaluation, *Molecules*, 2020, 25, 4485, DOI: [10.3390/molecules25194485](https://doi.org/10.3390/molecules25194485).
- 24 S. Dhillon, Sitagliptin, *Drugs*, 2010, 70, 489–512, DOI: [10.2165/11203790-000000000-00000](https://doi.org/10.2165/11203790-000000000-00000).
- 25 J. Xing, R. Zhang, X. Jiang, T. Hu, X. Wang, G. Qiao, J. Wang, F. Yang, X. Luo, K. Chen, J. Shen, C. Luo, H. Jiang and M. Zheng, Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors, *Eur. J. Med. Chem.*, 2019, 163, 281–294, DOI: [10.1016/j.ejmech.2018.11.018](https://doi.org/10.1016/j.ejmech.2018.11.018).
- 26 X. Chang, D. Sun, D. Shi, G. Wang, Y. Chen, K. Zhang, H. Tan, J. Liu, B. Liu and L. Ouyang, Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy, *Acta Pharm. Sin. B*, 2021, 11, 156–180, DOI: [10.1016/j.apsb.2020.06.003](https://doi.org/10.1016/j.apsb.2020.06.003).
- 27 X. Jiang, J. Zhou, J. Ai, Z. Song, X. Peng, L. Xing, Y. Xi, J. Guo, Q. Yao, J. Ding, M. Geng and A. Zhang, Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: Design, synthesis, and structure–activity relationship study, *Eur. J. Med. Chem.*, 2015, 105, 39–56, DOI: [10.1016/j.ejmech.2015.10.005](https://doi.org/10.1016/j.ejmech.2015.10.005).
- 28 M. Patil, A. Noonikara-Poyil, S. D. Joshi, S. A. Patil, S. A. Patil, A. M. Lewis and A. Bugarin, Synthesis, molecular docking studies, and *in vitro* antimicrobial evaluation of piperazine and triazolo-pyrazine derivatives, *Mol. Divers.*, 2022, 26, 827–841, DOI: [10.1007/s11030-021-10190-x](https://doi.org/10.1007/s11030-021-10190-x).
- 29 R. Raveesha, K. Y. Kumar, M. S. Raghu, S. B. B. Prasad, A. Alsalmeh, P. Krishnaiah and M. K. Prashanth, Synthesis, *in silico* ADME, toxicity prediction and molecular docking studies of N-substituted [1,2,4]triazolo[4,3-a]pyrazine derivatives as potential anticonvulsant agents, *J. Mol. Struct.*, 2022, 1255, 132407, DOI: [10.1016/j.molstruc.2022.132407](https://doi.org/10.1016/j.molstruc.2022.132407).
- 30 G. Shan, Z. Peng, Y. Li, D. Li, Y. Li, S. Meng, L. Gao, J. Jiang and Z. Li, A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structure–activity relationships and anti-HCV activity in GS4.3 replicon cells, *J. Antibiot.*, 2011, 64, 177–182, DOI: [10.1038/ja.2010.161](https://doi.org/10.1038/ja.2010.161).
- 31 H. R. Lawrence, K. Mahajan, Y. Luo, D. Zhang, N. Tindall, M. Huseyin, H. Gevariya, S. Kazi, S. Ozcan, N. P. Mahajan and N. J. Lawrence, Development of Novel ACK1/TNK2 Inhibitors Using a Fragment-Based Approach, *J. Med. Chem.*, 2015, 58, 2746–2763, DOI: [10.1021/jm501929n](https://doi.org/10.1021/jm501929n).
- 32 M. M. Elbadawi, W. M. Eldehna, A. A. Abd El-Hafeez, W. R. Somaa, A. Albohy, S. T. Al-Rashood, K. K. Agama, E. B. Elkaeed, P. Ghosh, Y. Pommier and M. Abe, 2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights, *J. Enzyme Inhib. Med. Chem.*, 2022, 37, 355–378, DOI: [10.1080/14756366.2021.2015344](https://doi.org/10.1080/14756366.2021.2015344).
- 33 S. K. Balam, S. K. Krishnammagari, J. Soora Harinath, S. P. Sthanikam, S. S. Chereddy, V. R. Pasupuleti, N. K. Yellapu, V. G. R. Peddiahgari and S. R. Cirandur, Synthesis of N-(3-picoyl)-based 1,3,2λ⁵-benzoxazaphosphinamides as potential 11β-HSD1 enzyme



- inhibitors, *Med. Chem. Res.*, 2015, **24**, 1119–1135, DOI: [10.1007/s00044-014-1194-7](https://doi.org/10.1007/s00044-014-1194-7).
- 34 E. Jameel, H. Madhav, P. Agrawal, M. K. Raza, S. Ahmedi, A. Rahman, N. Shahid, K. Shaheen, C. H. Gajra, A. Khan, M. Z. Malik, M. A. Imam, M. Kalamuddin, J. Kumar, D. Gupta, S. M. Nayeem, N. Manzoor, A. Mohammad, P. Malhotra and N. Hoda, Identification of new oxospiro chromane quinoline-carboxylate antimalarials that arrest parasite growth at ring stage, *J. Biomol. Struct. Dyn.*, 2023, 1–22, DOI: [10.1080/07391102.2023.2188959](https://doi.org/10.1080/07391102.2023.2188959).
- 35 Z. Hu, H. Dong, Z. Si, Y. Zhao and Y. Liang, Synthesis and Antibacterial Activity of Novel Triazol[4,3-a]pyrazine Derivatives, *Molecules*, 2023, **28**, 7876, DOI: [10.3390/molecules28237876](https://doi.org/10.3390/molecules28237876).
- 36 R. Raveesha, M. G. D. Kumar and S. B. B. Prasad, Synthesis of 3-Trifluoromethyl-5,6-dihydro-[1,2,4]triazolo Pyrazine Derivatives and Their Anti-Cancer Studies, *Molbank*, 2020, **2020**, M1173, DOI: [10.3390/M1173](https://doi.org/10.3390/M1173).
- 37 D. Agarwal, R. D. Gupta and S. K. Awasthi, Are Antimalarial Hybrid Molecules a Close Reality or a Distant Dream?, *Antimicrob. Agents Chemother.*, 2017, **61**, DOI: [10.1128/AAC.00249-17](https://doi.org/10.1128/AAC.00249-17).
- 38 D. Johnson, I. Jenkins, C. Huxley, M. Coster, K. Lum, J. White, V. Avery and R. Davis, Synthesis of New Triazolopyrazine Antimalarial Compounds, *Molecules*, 2021, **26**, 2421, DOI: [10.3390/molecules26092421](https://doi.org/10.3390/molecules26092421).
- 39 P. Mignon, Influence of the π - π interaction on the hydrogen bonding capacity of stacked DNA/RNA bases, *Nucleic Acids Res.*, 2005, **33**, 1779–1789, DOI: [10.1093/nar/gki317](https://doi.org/10.1093/nar/gki317).
- 40 P. S. Sijwali and P. J. Rosenthal, Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 4384–4389, DOI: [10.1073/pnas.0307720101](https://doi.org/10.1073/pnas.0307720101).
- 41 P. A. Moura, J. B. Dame and D. A. Fidock, Role of Plasmodium falciparum Digestive Vacuole Plasmepsins in the Specificity and Antimalarial Mode of Action of Cysteine and Aspartic Protease Inhibitors, *Antimicrob. Agents Chemother.*, 2009, **53**, 4968–4978, DOI: [10.1128/AAC.00882-09](https://doi.org/10.1128/AAC.00882-09).
- 42 J. M. Matz, Plasmodium's bottomless pit: properties and functions of the malaria parasite's digestive vacuole, *Trends Parasitol.*, 2022, **38**, 525–543, DOI: [10.1016/j.pt.2022.02.010](https://doi.org/10.1016/j.pt.2022.02.010).
- 43 D. Jani, R. Nagarkatti, W. Beatty, R. Angel, C. Slebodnick, J. Andersen, S. Kumar and D. Rathore, HDP—A Novel Heme Detoxification Protein from the Malaria Parasite, *PLoS Pathog.*, 2008, **4**, e1000053, DOI: [10.1371/journal.ppat.1000053](https://doi.org/10.1371/journal.ppat.1000053).
- 44 R. Ettari, S. Previti, C. Di Chio and M. Zappalà, Falcipain-2 and Falcipain-3 Inhibitors as Promising Antimalarial Agents, *Curr. Med. Chem.*, 2021, **28**, 3010–3031, DOI: [10.2174/0929867327666200730215316](https://doi.org/10.2174/0929867327666200730215316).
- 45 P. S. Sijwali, B. R. Shenai and P. J. Rosenthal, Folding of the Plasmodium falciparum Cysteine Protease Falcipain-2 Is Mediated by a Chaperone-like Peptide and Not the Prodomain, *J. Biol. Chem.*, 2002, **277**, 14910–14915, DOI: [10.1074/jbc.M109680200](https://doi.org/10.1074/jbc.M109680200).
- 46 M. Mishra, V. Singh and S. Singh, Structural Insights Into Key Plasmodium Proteases as Therapeutic Drug Targets, *Front. Microbiol.*, 2019, **10**, 394, DOI: [10.3389/fmicb.2019.00394](https://doi.org/10.3389/fmicb.2019.00394).
- 47 J. Lin, X. Yan, Z. Chung, C. W. Liew, A. El Sahili, E. V. Pechnikova, P. R. Preiser, Z. Bozdech, Y.-G. Gao and J. Lescar, Inhibition of falcilysin from Plasmodium falciparum by interference with its closed-to-open dynamic transition, *Commun. Biol.*, 2024, **7**, 1070, DOI: [10.1038/s42003-024-06774-6](https://doi.org/10.1038/s42003-024-06774-6).
- 48 G. Wirjanata, J. Lin, J. M. Dziekan, A. El Sahili, Z. Chung, S. Tjia, N. E. Binte Zulkifli, J. Boentoro, R. Tham, L. S. Jia, K. D. Go, H. Yu, A. Partridge, D. Olsen, N. Prabhu, R. M. Sobota, P. Nordlund, J. Lescar and Z. Bozdech, Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development, *Cell Chem. Biol.*, 2024, **31**, 743–759, DOI: [10.1016/j.chembiol.2024.03.002](https://doi.org/10.1016/j.chembiol.2024.03.002).
- 49 S. Eagon, M. Howland, M. Heying, E. Callant, N. Brar, E. Pompa and J. P. Mallari, Identification of Plasmodium falciparum falcilysin inhibitors by a virtual screen, *Bioorg. Med. Chem. Lett.*, 2021, **52**, 128394, DOI: [10.1016/j.bmcl.2021.128394](https://doi.org/10.1016/j.bmcl.2021.128394).
- 50 G. Kahlon, R. Lira, N. Masvlov, E. Pompa, N. Brar, S. Eagon, M. O. Anderson, A. Andaya, J. P. Chance, H. Fejzic, A. Keniston, N. Huynh, N. Celis, B. Vidal, N. Trieu, P. Rodriguez and J. P. Mallari, Structure guided development of potent piperazine-derived hydroxamic acid inhibitors targeting falcilysin, *Bioorg. Med. Chem. Lett.*, 2021, **32**, 127683, DOI: [10.1016/j.bmcl.2020.127683](https://doi.org/10.1016/j.bmcl.2020.127683).
- 51 H. Guterres and W. Im, Improving Protein–Ligand Docking Results with High-Throughput Molecular Dynamics Simulations, *J. Chem. Inf. Model.*, 2020, **60**, 2189–2198, DOI: [10.1021/acs.jcim.0c00057](https://doi.org/10.1021/acs.jcim.0c00057).
- 52 L. Fusani, D. S. Palmer, D. O. Somers and I. D. Wall, Exploring Ligand Stability in Protein Crystal Structures Using Binding Pose Metadynamics, *J. Chem. Inf. Model.*, 2020, **60**, 1528–1539, DOI: [10.1021/acs.jcim.9b00843](https://doi.org/10.1021/acs.jcim.9b00843).
- 53 H. Madhav, S. A. Abdel-Rahman, M. A. Hashmi, M. A. Rahman, M. Rehan, K. Pal, S. M. Nayeem, M. T. Gabr and N. Hoda, Multicomponent Petasis reaction for the identification of pyrazine based multi-target directed anti-Alzheimer's agents: In-silico design, synthesis, and characterization, *Eur. J. Med. Chem.*, 2023, **254**, 115354, DOI: [10.1016/j.ejmech.2023.115354](https://doi.org/10.1016/j.ejmech.2023.115354).
- 54 K. Teilum, J. G. Olsen and B. B. Kragelund, Functional aspects of protein flexibility, *Cell. Mol. Life Sci.*, 2009, **66**, 2231–2247, DOI: [10.1007/s00018-009-0014-6](https://doi.org/10.1007/s00018-009-0014-6).
- 55 S. Fatima, D. G. Boggs, N. Ali, P. J. Thompson, M. C. Thielges, J. Bridwell-Rabb and L. Olshansky, Engineering a Conformationally Switchable Artificial Metalloprotein, *J. Am. Chem. Soc.*, 2022, **144**, 21606–21616, DOI: [10.1021/jacs.2c08885](https://doi.org/10.1021/jacs.2c08885).
- 56 X. Song, L. Bao, C. Feng, Q. Huang, F. Zhang, X. Gao and R. Han, Accurate Prediction of Protein Structural Flexibility



- by Deep Learning Integrating Intricate Atomic Structures and Cryo-EM Density Information, *Nat. Commun.*, 2024, **15**, 5538, DOI: [10.1038/s41467-024-49858-x](https://doi.org/10.1038/s41467-024-49858-x).
- 57 J. F. Fatriansyah, A. G. Boanerges, S. R. Kurnianto, A. F. Pradana, Fadilah and S. N. Surip, Molecular Dynamics Simulation of Ligands from *Anredera cordifolia* (Binahong) to the Main Protease (Mpro) of SARS-CoV-2, *J. Trop. Med.*, 2022, **2022**, 1–13, DOI: [10.1155/2022/1178228](https://doi.org/10.1155/2022/1178228).
- 58 S. Ghahremanian, M. M. Rashidi, K. Raeisi and D. Toghraie, Molecular dynamics simulation approach for discovering potential inhibitors against SARS-CoV-2: A structural review, *J. Mol. Liq.*, 2022, **354**, 118901, DOI: [10.1016/j.molliq.2022.118901](https://doi.org/10.1016/j.molliq.2022.118901).
- 59 I. Yasuda, K. Endo, E. Yamamoto, Y. Hirano and K. Yasuoka, Differences in ligand-induced protein dynamics extracted from an unsupervised deep learning approach correlate with protein–ligand binding affinities, *Commun. Biol.*, 2022, **5**, 481, DOI: [10.1038/s42003-022-03416-7](https://doi.org/10.1038/s42003-022-03416-7).
- 60 T. Yu, N. Sudhakar and C. D. Okafor, Illuminating ligand-induced dynamics in nuclear receptors through MD simulations, *Biochim. Biophys. Acta - Gene Regul. Mech.*, 2024, **1867**, 195025, DOI: [10.1016/j.bbagr.2024.195025](https://doi.org/10.1016/j.bbagr.2024.195025).
- 61 S. De Vita, M. G. Chini, G. Bifulco and G. Lauro, Insights into the Ligand Binding to Bromodomain-Containing Protein 9 (BRD9): A Guide to the Selection of Potential Binders by Computational Methods, *Molecules*, 2021, **26**, 7192, DOI: [10.3390/molecules26237192](https://doi.org/10.3390/molecules26237192).
- 62 S. Manzoor, S. K. Prajapati, S. Majumdar, K. Raza, M. T. Gabr, S. Kumar, K. Pal, H. Rashid, S. Kumar, S. Krishnamurthy and N. Hoda, Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer's action: Design, synthesis, crystal structure and in-vitro biological evaluation, *Eur. J. Med. Chem.*, 2021, **215**, 113224, DOI: [10.1016/j.ejmech.2021.113224](https://doi.org/10.1016/j.ejmech.2021.113224).
- 63 H. Hu, Y. Dong, M. Li, R. Wang, X. Zhang, P. Gong and Y. Zhao, Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine and quinazoline derivatives as potent antitumor agents, *Bioorg. Chem.*, 2019, **90**, 103086, DOI: [10.1016/j.bioorg.2019.103086](https://doi.org/10.1016/j.bioorg.2019.103086).
- 64 A. Singh, M. Kalamuddin, M. Maqbool, A. Mohammed, P. Malhotra and N. Hoda, Quinoline carboxamide core moiety-based compounds inhibit *P. falciparum* falcipain-2: Design, synthesis and antimalarial efficacy studies, *Bioorg. Chem.*, 2020, 104514, DOI: [10.1016/j.bioorg.2020.104514](https://doi.org/10.1016/j.bioorg.2020.104514).
- 65 M. Smilkstein, N. Sriwilajaroen, J. X. Kelly, P. Wilairat and M. Riscoe, Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening, *Antimicrob. Agents Chemother.*, 2004, **48**, 1803–1806, DOI: [10.1128/AAC.48.5.1803-1806.2004](https://doi.org/10.1128/AAC.48.5.1803-1806.2004).
- 66 K. Pal, M. K. Raza, J. Legac, A. Rahman, S. Manzoor, S. Bhattacharjee, P. J. Rosenthal and N. Hoda, Identification, in-vitro anti-plasmodial assessment and docking studies of series of tetrahydrobenzothieno[2,3-d]pyrimidine-acetamide molecular hybrids as potential antimalarial agents, *Eur. J. Med. Chem.*, 2023, **248**, 115055, DOI: [10.1016/j.ejmech.2022.115055](https://doi.org/10.1016/j.ejmech.2022.115055).
- 67 T. A. Halgren, Identifying and Characterizing Binding Sites and Assessing Druggability, *J. Chem. Inf. Model.*, 2009, **49**, 377–389, DOI: [10.1021/ci800324m](https://doi.org/10.1021/ci800324m).
- 68 R. A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, P. C. Sanschagrin and D. T. Mainz, Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein–Ligand Complexes, *J. Med. Chem.*, 2006, **49**, 6177–6196, DOI: [10.1021/jm051256o](https://doi.org/10.1021/jm051256o).
- 69 V. Pandya, P. Rao, J. Prajapati, R. M. Rawal and D. Goswami, Pinpointing top inhibitors for GSK3 β from pool of indirubin derivatives using rigorous computational workflow and their validation using molecular dynamics (MD) simulations, *Sci. Rep.*, 2024, **14**, 49, DOI: [10.1038/s41598-023-50992-7](https://doi.org/10.1038/s41598-023-50992-7).

